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Abstract
Tobacco smoking is the leading cause of preventable death in the United States. Billions of
dollars are lost yearly in direct and indirect healthcare costs as well as lost work productivity due
to smoking. While smoking rates have declined among those of the general population, they
remain high among those with serious mental illness (SMI). Many of those with SMI desire to
quit and are able to quit smoking when they are provided with appropriate interventions and
resources. It is recommended for those with SMI to receive combined interventions in the form
of pharmacotherapy and cognitive behavioral therapy to help them quit. This Doctor of Nursing
Practice Scholarly Project is a quality improvement and evidence-based practice initiative to
develop and implement a group smoking treatment program within a Midwestern community
mental health organization.
Keywords: tobacco smoking, serious mental illness, smoking cessation, community
mental health
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Improving a Midwestern Community Mental Health Organization's Smoking Treatment Services
for Individuals with Serious Mental Illness
Tobacco smoking is harmful to almost every organ of the human body (Smokefree.gov,
n.d.) and is associated with many chronic diseases, including multiple forms of cancer (American
Cancer Society, 2015). Smoking is also the leading cause of preventable death in the United
States (U.S.; Centers for Disease Control and Prevention [CDC], 2018), and is attributed to more
than 520,000 deaths per year (Colton & Manderschied, 2006). The economic burden of tobacco
smoking is staggering. It is estimated that the U.S. spends nearly $300 billion per year on
medical care and lost productivity related to smoking (Xu, Bishop, Kennedy, Simpson, &
Pechacek, 2015). Fortunately, smoking rates have declined from 43% of U.S. adults in 1965 to
18% of U.S. adults today (Hall & Doran, 2016). Despite this statistic, tobacco smoking remains
prevalent among those with serious mental illness (SMI).
To clarify, SMI is a term to describe:
Persons aged 18 or older who currently or at any time in the past year have had a
diagnosable mental, behavioral, or emotional disorder (excluding developmental and substance
use disorders) of sufficient duration to meet diagnostic criteria within the DSM-5 that has
resulted in serious functional impairment, which substantially interferes with or limits one or
more major life activities. (Center for Substance Abuse Treatment, 1998, p. 265)
It is estimated that nearly 62% of those with schizophrenia and 37% of those with bipolar
disorders smoke (Dickerson et al., 2018), and people with mental illness purchase about half of
the cigarettes sold in the U.S. (Prochaska, Das, & Young-Wolff, 2017). Sadly, individuals with
SMI account for 200,000 of the 520,000 annual smoking-related deaths in the U.S. (Colton &
Manderschied, 2006). Further, individuals with SMI live on average about 25 years less than
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those of the general population, with much of this decreased life expectancy attributed to the
health effects of smoking (Colton & Manderschied, 2006). Many people with SMI desire to quit
and are able to quit smoking, and smoking cessation is associated with improvements in mental
health (Prochaska et al., 2017).
Evidence-based guidelines to help individuals with SMI quit smoking exist (Substance
Abuse and Mental Health Services Administration [SAMHSA], 2009). Despite this information,
people with SMI experience many barriers to quitting. Some of these barriers include the
attitudes and beliefs of health care providers. Many providers believe that individuals with SMI
do not want to quit and cannot quit smoking, more important matters exist than becoming smoke
free, and smoking abstinence is dangerous for mental health (Prochaska et al., 2017). These
false beliefs result in provider acceptance of smoking and a decreased likelihood that those with
SMI will receive proper assistance with smoking cessation (Sharma, Gartner, & Hall, 2016).
Current smoking treatment guidelines for those with SMI recommend a combined
approach of pharmacotherapy and cognitive behavioral therapy (CBT) delivered in either an
individual or group setting (SAMHSA, 2009). Individuals with SMI often experience social
isolation and stigmatization (Sharma et al., 2016), therefore a group smoking treatment program
offered in a community mental health organization (CMHO) may foster peer support as well as
provide comfort for treatment (Prochaska et al., 2017). Further, group programs are costeffective, and integration into CMHOs increases the receipt of tobacco treatment services
(Prochaska et al., 2017). Therefore, the purpose of this scholarly Doctor of Nursing Practice
(DNP) project is to develop and integrate an evidence-based group smoking treatment program
into a Midwestern CMHO to improve smoking treatment services within the organization as well
as to positively impact the smoking rates of participants involved in the program.
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Assessment of the Organization
An appropriate DNP project for the CMHO came to fruition based on the findings of an
organizational assessment (OA). To clarify, an OA is a procedure in which information is
obtained that measures an organization’s performance; the factors that affect performance; and
the organization’s strengths, weaknesses, and opportunities for change (Reflect & Learn, n.d.).
These next few sections will explain the framework used to guide the OA; describe current
CMHO practices that address tobacco smoking; and assess the CMHO’s strengths, weaknesses,
opportunities, and threats for change.
Framework for Assessment
The Institutional Organizational Assessment (IOA) Model was used as a framework to
help the DNP student perform a thorough assessment of the CMHO. The IOA Model, in
Appendix A, guides understanding of an organization’s functioning and opportunities for
performance improvement in three ways: 1) capacity, 2) external environment, and 3) motivation
(Universalia, n.d.). With the IOA Model as a guide, the OA was completed by interviewing and
shadowing key stakeholders (clients, nurse practitioners (NPs), registered nurses (RNs),
psychiatrists, social workers, peer supports, managerial staff), researching the organization’s
website, as well as examining annual reports. By utilizing the IOA model, current smoking
treatment practices were identified and a SWOT (Strengths, Weaknesses, Opportunities, and
Threats) analysis was used to organize the assessment findings.
Current Smoking Treatment Practices
Currently, standardized smoking cessation treatment services within the CMHO are
limited. Clients are questioned about tobacco smoking practices during the intake process for
medication reviews, but they are not asked whether they have thought about quitting or if they
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are interested in quitting. Prescribers at the CMHO state that they are willing to prescribe
medications, such as nicotine replacement therapy (NRT), to assist with quitting. However,
smoking cessation medications are not mentioned to the client unless the client expresses a desire
to quit. This type of approach is unstructured, permissive of smoking, and places the
responsibility of initiating change talk of smoking cessation entirely upon clients. This finding is
supported in the literature as a barrier to smoking cessation, as many people with SMI report a
lack of encouragement from healthcare providers to quit (Trainor & Leavey, 2017). This lack of
encouragement may be partially attributed to provider confusion over who is responsible for
addressing the matter (Malone, Harrison, & Daker-White, 2018). It is important to note that
because smoking treatment programs do not currently exist within the CMHO, there is no
baseline data to report.
SWOT
Performing an OA of the CMHO led to the discovery of certain factors that may help or
hinder the development of a group smoking treatment program. It is important to identify the
organization’s strengths, weaknesses, opportunities, and threats to determine whether or not a
group smoking treatment program is appropriate for the CMHO. This information is organized
by SWOT analysis, found in Appendix B.
Strengths.
Many organizational strengths support the development and integration of a group
smoking treatment program into the CMHO. First, this type of program aligns with the
organization’s mission statement: “XXXXXXXX XX XXXXXXXX is dedicated to
collaborative delivery of evidence-supported mental health and substance abuse treatments that
foster hope and wellness” (XXXa, n.d.). This intervention also promotes two components of the
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organization’s strategic plan for 2018-2021: “Identify and prioritize training in best practices in
each department,” and “Implement continuous service improvements” (XXXb, n.d.). The
organizational culture is supportive for this intervention, as staff are vested in their clients’ health
and well-being. One interviewed case worker explained that she knows a few clients who would
be very interested in a group smoking treatment program. Another staff member expressed,
“Community-wide, we’ve lost places where clients can go. The benefit of having groups is that
they keep people out of isolation and help them socialize.” This implies that a group smoking
treatment program would also provide psychosocial benefits to its members. Lastly, the CMHO
has the necessary physical space for a group program, as it currently conducts group programs
within its facility.
Weaknesses.
An organizational weakness that may impede the sustainability of a smoking cessation
initiative is funding. The CMHO receives most of its program funding through Medicaid. An
interview with the site director revealed current struggles with Medicaid funding, as the director
expressed, “…we are being paid less for certain services, like Assertive Community Treatment,
than what we were paid 10 years ago.” Another weakness is that there is currently only one
prescriber handling the psychiatric medication prescriptions for the entire caseload of the
organization’s clients. This may present as a prescribing challenge to the group program if
clients are interested in pharmacotherapeutic support for smoking treatment.
Opportunities.
The organization provides a few opportunities for the development of a group smoking
treatment program. The prevalence of tobacco smoking among those with SMI is higher than the
national rate (Dickerson et al., 2018; Prochaska et al., 2017), creating an opportunity for high
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impact for improved health outcomes. Additionally, client and staff buy-in for smoking treatment
presents an opportunity to implement an intervention that addresses this public health problem.
A group smoking treatment program would address these opportunities while improving the
CMHO’s smoking treatment services.
Threats.
One of the greatest threats to a group smoking treatment program involves client
transportation. Many of the organization’s clients do not drive and depend on staff, family,
friends, or the local bus system for travel to and from the organization. This dependence may
affect whether or not a client is able to attend group sessions regularly. Another threat to the
program is sustainability, which will likely depend on the success of the program (e.g., rates of
smoking reduction among participants). Because success may be an ambiguous term in certain
contexts, it is vital to determine and define project outcomes that will be interpreted as success.
This idea will be discussed further in the measures section of this paper. The findings of this OA
guided the DNP student with the next step of the project: conducting a literature review.
Review of the Literature
Searching and reviewing the literature regarding a clinical problem reveals what is known
and unknown about the problem, as well as possible evidence-based interventions to counter it.
As stated previously, it is recommended for individuals with SMI to receive tobacco smoking
treatment in the form of combined pharmacotherapy and CBT in either an individual or group
setting (SAMHSA, 2009). Therefore, to help inform this project, a literature review was
conducted to discover safe and effective smoking cessation therapies for those with SMI in the
form of combined pharmacotherapy and CBT.

IMPROVING A MIDWESTERN COMMUNITY MENTAL HEALTH

11

Method
The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA)
guideline served as the framework for this review (Moher, Liberati, Tetzlaff, Altman, & The
PRISMA Group, 2009). A comprehensive search limited to the English language and within the
past five years (2013-2018) was conducted in the electronic databases: The Cochrane Library,
CINAHL, and PubMed. Keywords included: serious mental illness, severe mental illness,
schizophrenia, bipolar disorder, smoking cessation, quitting smoking, combined interventions,
behavioral, cognitive behavioral therapy, group therapy, pharmacotherapy, varenicline,
bupropion, and nicotine replacement therapy.
Inclusion and exclusion criteria.
In order to yield relevant search results, inclusion and exclusion criteria were applied.
Population criteria included: adults ages 18 and older with a diagnosis of SMI. Specific SMI
diagnoses included: psychotic disorders, schizophrenia, schizoaffective disorder, major
depressive disorders, bipolar disorders, post-traumatic stress disorder (PTSD), and borderline
personality disorder. Population criteria excluded: individuals less than 18 years of age and
mental health diagnoses other than those listed above. To reflect the CMHO where this project
will take place, setting criteria included organizations such as community mental health and
military health centers where outpatient mental health programs are offered. Exclusion criteria
included inpatient settings and mixed inpatient and outpatient settings.
To reflect current guidelines on tobacco treatment for those with SMI (SAMHSA, 2009),
intervention characteristics included combined pharmacotherapy and CBT. Studies providing
Food and Drug Administration (FDA) approved pharmacotherapy for smoking cessation (NRT,
bupropion, varenicline; 2017) were included. Studies incorporating non-FDA approved
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pharmacotherapy (e.g., clonidine, nortryptiline, electronic cigarettes, vape pens) were excluded.
Studies involving CBT delivered face-to-face in either individual or group settings were
included. Studies involving CBT delivered over the phone or in other electronic form were
excluded. Studies involving behavioral interventions listed as advice were excluded.
PRISMA.
Initial search results of the listed databases yielded 137 CINAHL articles, three Cochrane
reviews, and 17 PubMed articles (see Appendix C). After initial review, 122 non-duplicative
citations were screened. Seven articles were retrieved after inclusion and exclusion criteria were
applied. After further screening, four articles were removed. As a result, three articles (Bennett
et al., 2015; Chengappa et al., 2014; Garcia-Portilla et al., 2016) were analyzed in the literature
review.
Summary of Results
Site/participant characteristics.
All three studies were performed in outpatient settings (Bennett et al., 2015; Chengappa
et al., 2014; Garcia-Portilla et al., 2016). Two studies took place at outpatient mental health
clinics in the U.S. (Chengappa et al., 2014) and Spain (Garcia-Portilla et al., 2016). The Bennett
et al. (2015) study took place at outpatient Veterans Affairs medical centers in the U.S. All three
studies included male and female participants ages 18 and older (Bennett et al., 2015; Chengappa
et al., 2014; Garcia-Portilla et al., 2016). The combined SMI diagnoses of the studies included:
bipolar disorders, schizophrenia spectrum disorders, other psychotic disorder, affective
psychosis, major depression with psychotic features, and PTSD (Bennett et al., 2015; Chengappa
et al., 2014; Garcia-Portilla et al., 2016).
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It is important to note the psychiatric stability of the studies’ participants. Participants
were excluded from two studies if they had any history of psychiatric emergency room visits or
hospital stays, suicide attempts, or aggressive and violent acts within the previous six months
(Chengappa et al., 2014; Garcia-Portilla et al., 2016). Participants were excluded from all three
of the studies if they had any current or recent drug or alcohol abuse (Bennett et al., 2015;
Chengappa et al., 2014, Garcia-Portilla et al., 2016). Additionally, the Chengappa et al. (2014)
study excluded participants who were acutely manic or depressed, and the Garcia-Portilla et al.
(2016) study excluded participants if they were acutely depressed or psychotic.
Intervention characteristics.
All three studies involve participants partaking in a combined smoking cessation
intervention involving pharmacotherapy and CBT (Bennett et al., 2015; Chengappa et al., 2014;
Garcia-Portilla et al., 2016). The differences among study interventions include: type of
delivered pharmacotherapies, behavioral intervention format, format of delivery, and
characteristics of comparison interventions (if any).
Pharmacotherapy.
The main focus of the Chengappa et al. (2014) study was to determine the effectiveness
of varenicline as compared to placebo when used for smoking cessation in those with bipolar
disorders. Study participants were randomized to either varenicline (titrated according to
standard instructions) or placebo over a series of 12 weeks (Chengappa et al., 2014). Two other
studies (Bennett et al., 2015; Garcia-Portilla et al., 2016) did not include randomization of
medication treatment, as participants were given the choice to partake in shared decision-making
with their mental health treatment teams if they desired pharmacotherapeutic support when
making quit attempts. One study allowed for shared decision-making to consider bupropion and
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NRT (Bennett et al., 2015), while the other study allowed these two modalities as well as
varenicline to be considered between participants and treatment teams (Garcia-Portilla et al.,
2016).
Behavioral therapy.
Assessing the format of delivered behavioral therapies among the three studies was an
important aspect of this review. One study’s primary focus was on the effectiveness of
varenicline for smoking cessation; however, participants in both the intervention and placebo
groups also received 15 minutes of individual CBT-focused smoking cessation counseling at
each visit (Chengappa et al., 2014). The study does not describe how many sessions participants
attended or describe the characteristics of the meetings; however, Chengappa et al. (2014) cite
the manual (Perkins, Conklin, & Levine, 2008) used to structure the meetings. This manual
educates providers on: the nature and consequences of tobacco dependence; preparing smokers
for quitting; medications to aid quitting; managing tobacco withdrawal and lapses in cessation;
managing issues with weight gain upon quitting; and procedures for follow-up and long-term
maintenance (Perkins et al., 2008).
Alternatively, another study compared a specialized behavioral treatment for smoking
cessation in persons with SMI to a standard supportive smoking cessation program (Bennett et
al., 2015). In this study, participants were randomized to either a behavioral treatment group or a
supportive smoking cessation program (Bennett et al., 2015). Participants in the behavioral
treatment received one individual meeting where consequences of smoking and reasons for
change were discussed (Bennett et al., 2015). Participants then attended 24 bi-weekly group
meetings where skills such as, coping with quitting, refusing smoking offers, and coping in highrisk smoking situations were taught (Bennett et al., 2015). Participants in the behavioral group
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also performed exhaled carbon monoxide (CO) readings before each meeting and received
feedback as well as small financial awards for readings less than 10 parts per million (ppm) that
increased in value if readings were maintained (Bennett et al., 2015). If participants were
interested in bupropion or NRT, study personnel assisted them with setting-up meetings with
their prescribers, and ensured that participants obtained medication if it was prescribed (Bennett
et al., 2015). Participants in the standard supportive smoking cessation program attended 24 biweekly non-tailored group meetings (Bennett et al., 2015). Group sessions in the supportive
program focused on harm from smoking and support for quitting, the habit of smoking, barriers
to quitting, and increasing confidence to quit (Bennett et al., 2015). Supportive program
participants also performed exhaled breath CO readings before each meeting, but the readings
were not disclosed to the participants (Bennett et al., 2015). Both groups were educated on
bupropion and NRT for smoking cessation assistance, however, additional medication support
was not provided to the members of the standard supportive smoking cessation program (Bennett
et al., 2015).
One study did not randomize their subjects to either behavioral or pharmacotherapeutic
interventions (Garcia-Portilla et al., 2016). In this study, participants completed two study
phases (Garcia-Portilla et al., 2016). Phase one included weekly motivational therapy for 4-12
weeks followed by phase two, where participants completed 12 weeks of group therapy relevant
to smoking cessation (Garcia-Portilla et al., 2016). Described previously, patients taking
smoking cessation medication began taking the medication during phase two (Garcia-Portilla et
al., 2016).
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Outcomes.
Seven-day point prevalence.
Seven-day point prevalence, that is, when one has not smoked tobacco during the
previous seven days (North American Quitline Consortium [NAQC], n.d.), was one of the main
outcomes of interest of each study (Bennett et al., 2015; Chengappa et al, 2014; Garcia-Portilla et
al., 2016). A positive response with seven-day point prevalence was observed with each study
(Bennett et al., 2015; Chengappa et al, 2014; Garcia-Portilla et al., 2016), and a significant
response (OR = 8.13; 95% CI, 2.03-32.53; P < .002) was observed in one study, with 15 of 31
(48.8%) varenicline-treated participants achieving abstinence at 12 weeks compared to 3 of 29
(10.3%) participants treated with placebo (Chengappa et al., 2014). Another study had similar
results, as 37 of 75 (49.3%) participants treated with varenicline or NRT achieved smoking
abstinence, with no statistically significant difference between medications (48.6% varenicline,
50% NRT; chi-square = 0.015, p = 1.000; Garcia-Portilla et al., 2016). In the Bennett et al.
(2015) study, 16 of 136 participants achieved abstinence; interestingly, there were no significant
differences (p = .379) between those who quit in the behavioral group (n/n=10/71, 14.1%)
compared to those who quit in the standard group (n/n = 6/65, 9.2%). However, those in the
behavioral group were more likely to try cessation medication than those in the standard group
(Bennett et al., 2015). This may be because participants in the behavioral group received
extended support for pharmacological smoking cessation treatment (Bennett et al., 2015).
Smoking reduction.
All three studies demonstrated a positive response to treatment in regard to smoking
reduction (Bennett et al., 2015; Chengappa et al., 2014; Garcia-Portilla et al., 2016). Participant
mean cigarette use in the Bennett et al. (2015) study declined from 15.2 (SD = 9.8) at baseline to
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7.7 (SD = 2.7) cigarettes smoked per day at post-treatment. Participants in the Chengappa et al.
(2014) study decreased mean cigarette use in the varenicline group by 84%, and 69% in the
placebo group. Lastly, by week 12 of the Garcia-Portilla et al. (2016) study, 81.3% of
participants reported a reduction of 50% or more in the number of cigarettes smoked per day,
with no significant differences between medication treatment groups (varenicline 82.9%, NRT
80.0%; chi-square = 0.100, p = 0.776).
Sustained smoking abstinence.
As with seven-day point prevalence, the Chengappa et al. (2014) study also found that
significantly more participants treated with varenicline achieved four-week continuous
abstinence (n/n = 11/31, 35.5%) than those treated with placebo (n/n = 3/29, 10.3%; OR = 4.77;
95% CI, 1.02-25.13; P = .032). Six months after treatment, 6 of 31 participants treated with
varenicline remained abstinent from smoking, compared to 2 of 29 participants treated with
placebo (OR = 3.2; 95% CI, 0.60-17.6; P = .17; Chengappa et al., 2014). At 24 weeks 41.3% of
participants in the Garcia-Portilla et al. (2015) study were abstinent, and at 36 weeks 37.3% of
participants were abstinent (with no difference between medication treatments).
Side effects/serious adverse events.
Interestingly, none of the trials reported serious adverse events (SAEs) that were likely
associated with study treatments (Bennett et al., 2015, Chengappa et al., 2014; Garcia-Portilla et
al., 2016). Chengappa et al. (2014) reported 10 SAEs that occurred during their study, with six
SAEs occurring within the varenicline group (n/n = 6/31, 19.4%), and four within the placebo
group (n/n = 4/29, 13.8%). Two of the SAEs in the varenicline group (n/n = 2/31, 6.5%) were
categorized as “possibly related” to medication (Chengappa et al., 2014). These SAEs included
the development of a rash in one event; and agitation, hostility, impulsive abuse of drugs and
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alcohol, homicidal intentions, and involuntary hospitalization in another event (Chengappa et al.,
2014). In the Garcia-Portilla et al. (2016) study, there were no reports of suicide attempts,
hospitalization, or worsening scores on psychiatric rating scales. Contrarily, there were
improved psychiatric rating scores the varenicline group concerning positive symptoms, general
psychopathology, and total scores (Garcia-Portilla et al., 2016).
The most common side effects reported with varenicline were abnormal dreams (n/n =
18/31, 58%; Chengappa et al., 2014), insomnia (n/n = 14/31, 45.2%; Chengappa et al., 2014),
constipation (n/n = 9/39, 23.1%; Garcia-Portilla et al., 2016), and nausea and vomiting (n/n =
13/31, 41.9%; Chengappa et al., 2014; n/n = 12/39, 30.8%; Garcia-Portilla et al., 2016). During
the Garcia-Portilla et al. (2016) study, due to elevated liver enzymes, one participant was
switched from varenicline to NRT and two other participants had their dosages of varenicline
lowered. Skin rash (n/n = 10/36, 27.8%) and abnormal dreams were the most common side
effects associated with NRT (n/n = 9/36, 25.0%; Garcia-Portilla et al., 2016). Unfortunately,
Bennett et al. (2015) did not report on participant side effects associated with NRT or bupropion.
Evidence to be used for Project
The results of the literature review reinforce SAMHSA (2009) guidelines in that
individuals with SMI are able to reduce and/or quit smoking with proper behavioral and
pharmacological support (Bennett et al., 2015; Chengappa et al., 2014; Garcia-Portilla et al.,
2016). This literature review provides evidence to inform the DNP project. This evidence will
be discussed in the next section.
Assistance with cessation medications.
An interesting finding in the Bennett et al. (2015) study is that participants in the
behavioral treatment group were more likely to try cessation medication (bupropion and/or NRT)
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than those in the standard treatment group; likely due to behavioral group participants receiving
assistance with setting-up meetings with prescribers, and ensuring participants received their
medications. This finding will be utilized toward the group smoking treatment program in that
participants will be assisted with setting-up meetings to talk with the CMHO prescriber(s) about
possible treatment, if they are interested. If a medication is prescribed, it will be ensured that the
participant(s) receive their medication and are taking it properly.
Medication safety.
Another finding of the studies involves the safety of the three medications (NRT,
bupropion, varenicline) used to assist participants with smoking cessation. None of the studies
reported SAEs that were related to study treatments (Bennett et al., 2015; Chengappa et al.,
2014; Garcia-Portilla et al., 2016). This indicates that NRT, bupropion, and varenicline are safe
medications to assist those with SMI in smoking cessation. Further, the findings associated with
participants treated with varenicline (Chengappa et al., 2014; Garcia-Portilla et al., 2016) reflect
the results of a large, double-blind, randomized, placebo-controlled trial testing the
neuropsychiatric safety and efficacy of varenicline in those with and without psychiatric
disorders (Anthenelli et al., 2016). The authors of this study concluded that there was no
significant increase in moderate-to-severe SAEs associated with varenicline in any participants,
regardless of whether or not they had a psychiatric disorder (Anthenelli et al., 2016). The results
of this study led the FDA to remove varenicline’s black box warning (Prochaska et al., 2017).
Although the safety of NRT, bupropion, and varenicline were reinforced by the findings
of the three studies, it is important to note the stable psychiatric health of the study participants
(Bennett et al, 2015; Chengappa et al., 2014; Garcia-Portilla et al., 2016). It is difficult to
determine if these safety findings would be transferrable to participants in the group smoking
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treatment program who may not have as stable of a psychiatric history in the recent past.
Therefore, decisions on what medication(s) to prescribe for participants will be made by the
CMHO prescriber(s); considering their expertise, relationship with participants, as well as
clinical judgment.
Clinical Practice Question
The CMHO serves a population of individuals in which the habit of tobacco smoking is
prevalent (Dickerson et al., 2018), and the health effects are devastating (American Cancer
Society, 2015; Colton & Manderscheid, 2006). The OA reveals that the CMHO needs
improvement in its practices of treating smoking among its clients. The literature review
reinforces the effectiveness of smoking treatments that incorporate medication as well as CBT
for those with SMI. Based on this information, the clinical practice question guiding this project
is: Does the design and implementation of an evidence-based group smoking treatment program
within the CMHO increase participant motivation and self-efficacy to quit smoking, as well as
decrease smoking rates?
Phenomenon Theories
Development of an effective and sustainable group smoking treatment program requires
guidance by two theories to help understand the process of smoking cessation. The two theories
that will be applied to this DNP project are the Transtheoretical Model of Health Behavior
Change (see Appendix D) and the Theory of Self-Efficacy (see Appendix E). The
Transtheoretical Model, developed by Prochaska and DiClemente (1984), proposes that health
behavior change occurs in five stages: precontemplation, contemplation, preparation, action, and
maintenance. It is proposed that in precontemplation, there is no plan for behavior change within
the next six months (Prochaska & Velicer, 1997). During contemplation, there is a plan for
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behavior change within the next six months (Prochaska & Velicer, 1997). Preparation is the
stage in which there is the plan for behavior change within the next month (Prochaska & Velicer,
1997). Action is the stage in which one has made a behavior change within the previous six
months (Prochaska & Velicer, 1997). The last stage, maintenance, occurs when there is active
work to sustain new health behaviors and the prevention of relapse (Prochaska & Velicer, 1997).
The Transtheoretical Model does not imply that health behavior change is a rigid step-bystep process. Rather, change is a process in which one may move back and forth in the stages of
change (Prochaska & Velicer, 1997). This is an important concept to note for this project, as
quitting smoking is regarded as “…a process rather than an event” (SAMHSA, 2009, p. 6), as
tobacco dependence is a disorder in which it typically requires multiple quit attempts before one
is able to permanently quit. This idea is especially important to consider when developing
project outcome measures. As mentioned previously, this rationalizes the need to develop a
variety of outcomes that define success.
The Theory of Self-Efficacy, developed by Bandura (1977), attempts to explain how selfefficacy, or one’s belief that they can achieve a goal or outcome, is affected by different factors.
Factors that affect self-efficacy include: performance accomplishments (e.g., past experiences),
vicarious experiences (e.g., modeling by others), social persuasion (e.g., coaching), and
physiological and emotional states (Bandura, 1977). The Theory of Self-Efficacy will be applied
to the DNP project to not only shape outcome measures but to also guide the DNP student in
developing lesson plans that enhance self-efficacy for participant smoking reduction and/or
cessation.
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Project Plan
The previous sections of this paper describe the problem of tobacco smoking among
those with SMI, and recognize the need for quality improvement within the CMHO in regard to
smoking treatment. The literature review, Transtheoretical Model, and Theory of Self-Efficacy
also provide key information in shaping the DNP project. The next few sections of this paper
will discuss the project plan. Specifically, the details of how and when the project will be
implemented, outcome measures, data collection/analysis, budget, and sustainability will be
discussed.
Project Goal, Aim, and Objectives
The overarching goal of this project is to develop and implement an evidence-based
group smoking treatment program to improve CMHO practices of smoking treatment in a
sustainable fashion, while fostering participant behavioral changes to reduce and/or quit
smoking. To promote sustainability, the aim and objectives of the program reflect the CMHO’s
mission of providing evidence-based treatments that foster hope and wellness (XXXa, n.d.).
Therefore, the major aim of the project is to develop and implement an evidence-based group
smoking treatment program that not only counters the behavioral and pharmacological
components of nicotine addiction, but also fosters capability and confidence in quitting smoking.
In order to achieve the overarching goal and meet the aim of the project, it is important to
develop specific project objectives. Because behavioral interventions will be delivered in a group
format, the first objective is that group logistics (number of sessions, session length, session
topics) will be mindfully structured according to information provided in The SANE Smokefree
Kit (SANE Australia, 2009) and Treatment Manual for Smoking Cessation Groups: A Guide for
Therapists (Stritzke, Chong, & Ferguson, 2009). The SANE Smokefree Kit (SANE Australia,
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2009) is a research-based guide to help individuals with mental illness quit smoking. More
specifically, The SANE Smokefree Kit (SANE Australia, 2009):
Includes a Quit Smoking Program specifically designed to help address the needs of
people with a mental illness. Blending traditional smoking cessation theories and principles with
expertise and knowledge from the mental health field, this Program gives people with mental
illness a realistic opportunity to quit or reduce smoking (“Introduction,” para. 4).
The Treatment Manual for Smoking Cessation Groups: A Guide for Therapists (Stritzke
et al., 2009) serves as a reference to help less-experienced providers facilitate a group smoking
treatment intervention. The Treatment Manual for Smoking Cessation Groups: A Guide for
Therapists “…has two aims: (a) to translate international clinical practice guidelines into stepby-step instructions for setting up, conducting, and evaluating a group intervention for smoking
cessation; and (b) to provide ready-to-use client materials and treatment tools (Stritzke et al.,
2009, p. viii).
According to SAMHSA (2009) guidelines, behavioral interventions for smoking
treatment in those with SMI should involve therapies grounded in CBT, including problem
solving and skills training. Therefore, the second objective of this program is to incorporate
CBT techniques into group sessions to help foster self-confidence, motivation, and skills to
reduce and/or quit smoking. The Treatment Manual for Smoking Cessation Groups: A Guide for
Therapists (Stritzke et al., 2009), The SANE Smokefree Kit (SANE Australia, 2009), as well as
Cognitive-Behavioral Therapy for Smoking Cessation: A Practical Guidebook to the Most
Effective Treatments (Perkins et al., 2008) will be utilized as guides for these techniques.
Cognitive-Behavioral Therapy for Smoking Cessation: A Practical Guidebook to the Most
Effective Treatments (Perkins et al., 2008) presents counseling methods to help individuals quit
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smoking as well as “…techniques to address individual differences in the cessation-related
problems that impede a smoker’s ability to quit” (p. xi).
Thus far, the described objectives primarily address the aim involving evidence and
guidelines to address the behavioral aspects of nicotine addiction in those with SMI. It is also
important to develop objectives that address the pharmacological aspects of nicotine addiction.
Therefore, the third objective of the program is to develop a process in which group participants
interested in pharmacologic aids for smoking cessation may meet with CMHO prescriber(s) to
discuss options.
Ethics and Protection for Human Subjects
Consideration of ethics and protection for human subjects is required for this project.
The CMHO does not have an Institutional Review Board (IRB); therefore, the DNP student
utilized the Grand Valley State University Human Research Review Committee IRB for project
approval. As evidenced in Appendix F, this DNP project did not meet the qualifications of
human research, and was approved.
Design and Setting for the Evidence-Based Intervention
This DNP project seeks to meet the CMHO’s strategic plan objective “Implement
continuous service improvements” (XXXb, n.d.). Therefore, the design for this DNP project
aligns with that of quality improvement and evidence-based practice integration. The CMHO
has two sites, location A and location B that were opened in 1991 and 2013, respectively. The
DNP project will take place at location B, and future use of the term “CMHO” and
“organization” pertains to this location only. The CMHO offers a variety of services to its clients
with SMI. Assertive Community Treatment involves a team-based approach to help individuals
live successfully and independently in the community (XXXa, n.d.). Action Employment
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Services, modeled after an evidence-based framework, helps individuals find, choose, and
maintain employment (XXXa, n.d.). Dialectical Behavior Therapy services involve the
utilization of evidence-based individual therapy and skills training to help those who have
challenges with interpersonal relationships, self-harm urges, and intense emotions (XXXa, n.d.).
Community Payee Services help people (designated by the Social Security Administration) with
money management (XXXa, n.d.). Navigate is a service helping individuals ages 15-30 with
symptom improvement, relapse reduction, and success with employment, relationships, and
independent living after experiencing a first episode of psychosis (XXXa, n.d.). Lastly, the
CMHO offers Substance Abuse Services and provides a co-occurring disorders group for eligible
and willing participants (XXXa, n.d.). In the most recent published review (fiscal year 20162017), both locations A & B served a combined total of 2,426 individuals through its various
programs (XXXa, 2018). Location B served 233 clients with ACT services (XXXa, 2018).
The CMHO staff includes: social workers, RNs, NPs, psychiatrists, peer supports,
managerial staff, and support staff. Prescribing staff includes NPs and psychiatrists. Up until
recently, two NPs and one psychiatrist were responsible for the prescribing of psychiatric
medications to the clients served by the CMHO. Currently, there is one NP who is responsible
for the prescribing of psychiatric medications.
During the OA, the DNP student met with the CMHO site director. The DNP student
discussed various project topics with the site director, including that of a group smoking
treatment program. Verbal consent by the site director was given to the DNP student to proceed
with a group smoking treatment program.
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Participants
The target population of the DNP project includes adult clients ages 18 and older of any
gender or race with SMI who are serviced by any of the three CMHO ACT teams. Clients with
SMI diagnoses consistent with the previously described definition of SMI will be considered.
The project will seek participants who are contemplating or preparing to quit smoking.
However, clients in any stage of health behavior change pertaining to smoking cessation are
welcome to join if they are interested, as the program may help move an individual from
precontemplation to contemplation and preparation. Exclusion criteria will include clients who
are acutely physically or mentally ill to the point where they are unable to participate in group
sessions. It is recommended to keep a small group size (5-10 participants) in smoking programs
with one facilitator (SANE Australia, 2009); therefore this is the goal for the number of
participants for this project. However, because attrition is likely to occur, enrolling up to 15
participants will be considered.
Model Guiding Implementation
The model guiding the development and implementation of this DNP project, seen in
Appendix G, is the Model for Evidence-Based Practice Change (MEBPC). The MEBPC
explains the six necessary steps for implementation of evidence-based practices for quality
improvement (Larrabee, 2004). Discussion on application of the MEBPC to this project is
described subsequently.
Step 1: Assess the need for change in practice.
Step 1 of the MEBPC involves the identification of opportunities for improvement within
an organization to help guide Step 2 (Melnyk & Fineout-Overholt, 2015). Performing an OA of
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the CMHO completed step 1 of this DNP project. Results of the OA revealed an organizational
need for improvement in services treating tobacco smoking among its clients.
Step 2: Locate the best evidence, and Step 3: Critically analyze the evidence.
Steps 2 and 3 of the MEBPC involve searching for the best evidence, rigorously
analyzing the evidence, and determining whether or not the evidence has the strength and quality
to support practice change (Melnyk & Fineout-Overholt, 2015). Steps 2 and 3 of this DNP
project were achieved through completion of the literature review. Several evidential findings
from the literature review will be used to shape the project interventions.
Step 4: Design practice change.
Step 4 of the MEBPC includes the processes of “…defining the proposed practice
change; identifying needed resources; designing the evaluation of the pilot; and designing the
implementation plan” (Melnyk & Fineout-Overholt, 2015, p. 288). Step 4 is essentially what this
paper entails: proposing the need for practice change within the CMHO and the processes that
involve it. One of these processes includes the implementation steps and strategies, and the
timeline of when these items will take place (see Appendix H).
Implementation steps, strategies, and timeline.
Implementation of this DNP project includes:
• Raising awareness among ACT teams. The DNP student sent an email on
September 12th informing ACT team members and organizational leaders of the
impending DNP project, as well as a request to fill-out a survey that will be
emailed within the next few weeks.
• Collecting ideas/opinions. Powell et al. (2015) recognize that promoting
adaptability is an effective implementation strategy to preserve fidelity. Because
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group participants are enrolled in ACT services, the opinions of ACT team
members are highly valued in shaping this project. To promote adaptability, a
survey created by the DNP student through Typeform© will be emailed out to
ACT team case workers by November 1st. This survey will focus on the logistics
of group meetings (number of meetings per week, length of meetings), and will
attempt to capture the perceived value of the intervention. Two weeks will be
given for respondents to fill-out the survey.
• Designation of group date/time. By November 21st the DNP student will meet
with the CMHO operations manager to designate a weekly date and time that the
CMHO group room will be dedicated to the smoking treatment group. The survey
results will be brought to this meeting to help inform the designated dates and
times. During this meeting, the DNP student will also discuss requirements of how
group sessions will be charted in the participants’ electronic health records.
• Communication with ACT teams. By November 27th the DNP student will
communicate the results of the survey as well as designated dates and times of the
group program to the ACT teams, providers, and management personnel through
email.
• Education session with ACT teams. Powell et al. (2015) recognize the
development and distribution of educational materials as well as conducting
educational meetings as effective implementation strategies. By November 30th
the DNP student will meet with each of the ACT teams during their morning
meetings, provide education on the goals of the group program, discuss
enrollment, and distribute client education forms, shown in Appendix I, as well as
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pre-enrollment forms, shown in Appendix J. The DNP student will collect the preenrollment forms by December 7th.
• Developing a plan for pharmacotherapy. By December 14th, the DNP student will
meet with CMHO prescriber(s) to develop a plan for prescribing
pharmacotherapies for interested participants.
• First contact and enrollment. The DNP student will call pre-enrolled clients and
confirm that they are indeed interested in enrolling in the group program. If so, by
December 21st the DNP student will meet with each participant in person to
provide group dates and times as well as to fill-out the program enrollment form
(see Appendix K).
o Notification of staff. As participants enroll, the DNP student will send an
email notifying the ACT teams, prescriber(s), and managerial staff of
enrolled clients and whether or not they will need transportation to the
group meetings.
• Reminder calls. Powell et al. (2015) explain how the use of reminders prompts the
use of an intervention. The DNP student will call the enrolled participants and
remind them of the group approximately 1-2 days before the start date (week of
December 31st). The DNP student will then place reminder calls each week 1-2
days before group.
• Group implementation. It is estimated that the group smoking treatment program
will run once per week for eight weeks. The DNP student is currently estimating
that group sessions will begin the week of January 8th, and take place one day per
week, with the last session occurring the week of February 25th.
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o Documentation of group plans/activities: Bonnel and Smith (2018)
explain that it is important to describe interventions in sufficient detail so
they may be replicated. The exact topics/activities for each group session
have not been decided as of this moment, but will be determined by the
SANE Smokefree Kit (SANE Australia, 2009). The DNP student will
document the plans for each group session in detail 1-2 weeks before each
group session.
o Keeping communication open. During this phase the DNP student will
present to ACT team meetings and prescriber(s) once per week to ask if
there are any questions or concerns regarding clients who are partaking in
the group program. Powell et al. (2015) explain that this implementation
strategy is used to improve quality by monitoring progress and inquiring
about areas for improvement.
•

Data analysis. Powell et al. (2015) indicate the use of data experts as an
implementation strategy to inform the success of a project. The DNP student will
meet with a statistician by March 8th to discuss analysis of collected data.

•

Dissemination of results to CMHO stakeholders. The DNP student will hold a
meeting with CMHO stakeholders to discuss the results of the group smoking
treatment program. During this meeting, sustainability of the program will be
discussed. This meeting will take place the week of March 11th.

•

Sustainability. The DNP student will develop a sustainability plan for the group
smoking treatment program by the week of March 18th.
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Defense. The DNP student will defend the group smoking treatment program at
Grand Valley State University by the week of April 15th.

Step 5: Implement and evaluate change in practice.
Step 5 of the MEBPC includes applying the steps and strategies described in Stage 4 to
implement the DNP project (Melnyk & Fineout-Overholt, 2015). Data is collected during
implementation and after project completion to determine the success of the project as well as to
“…adapt, adopt, or reject the new practice” (Melnyk & Fineout-Overholt, 2015, p. 289). It is
crucial to understand that quitting smoking is a difficult, non-linear process, where individuals
commonly experience set-backs and relapse that may be interpreted as failure (Stritzke et al.,
2009). Because of this matter, it is recommended to set a low threshold of success, so those
attempting to quit smoking experience small successes that bolster self-esteem and confidence in
quitting. Therefore, it is important to understand that smoking cessation and sustained smoking
abstinence are not the main determinants of success for this DNP project. Further, this is the
reason that this project is named as a group smoking treatment program rather than group
smoking cessation program. The next few sections will define the measures used to gauge the
success of the project.
Measures.
Smoking reduction.
An outcome measure of this DNP project will be smoking reduction; that is, reduction in
the number of cigarettes smoked per day from baseline assessment (Hughes & Carpenter, 2005).
Not only is smoking reduction important in that it instills feelings of success and motivation in
those who experience it, but it is also proven that those who are able to reduce smoking are likely
to make further quit attempts and achieve abstinence in the future (Tidey & Miller, 2015).
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Carbon monoxide is a dangerous gas found in tobacco smoke that enters an individual’s
blood stream through their lungs when they smoke (Stritzke et al., 2009). As an individual
reduces the amount that they smoke, their exhaled CO levels reduce as well (Perkins et al.,
2008). This is rewarding for individuals, as they experience a tangible health benefit for their
efforts, progress toward health goals (Stritzke et al, 2009), and a form of positive reinforcement
(Perkins et al, 2008). Therefore, individuals will be provided their exhaled CO levels for
motivational purposes only (see Appendix L). The Covita™ piCO™ + Smokerlyzer® will be the
tool used for measurement of exhaled CO levels.
Smoking cessation and sustained smoking cessation.
Although smoking cessation is not a primary outcome of interest for this DNP project,
this does not indicate that it should not be an outcome measure. This reinforces false beliefs that
those with SMI cannot quit smoking (Prochaska et al., 2017). One or more group participants
may reach smoking cessation during the project. Therefore, this outcome will be measured
through self-report of seven-day point prevalence abstinence and verified by concentrations of
exhaled CO. If one or more group participants are able to achieve smoking cessation during the
project, and are able to maintain smoking abstinence until the end of the project, the individual
will be contacted one month after project completion to determine whether or not they have
maintained smoking abstinence. If so, an attempt will be made to verify this self-report by
measuring concentrations of exhaled CO.
Stage of health behavior change for smoking reduction/cessation.
Rustin and Tate (1993) explain that measuring changes in smoking amount alone is
inadequate when measuring the success of smoking cessation treatments. Rather, success is also
defined as the forward movement of individuals from one stage of change to the next (Rustin &
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Tate, 1993). Therefore, group participants in this intervention will be assessed for their stage of
change according to the Transtheoretical Model. The instrument used to measure this outcome
will be the Contemplation Ladder (see Appendix M). The Contemplation Ladder, developed by
Biener and Abrams (1991), measures the stage of change an individual is at considering their
readiness for smoking cessation. The Ladder has concurrent validity, as it is significantly
correlated with the likelihood of making a quit attempt within the next six months (p < .001;
Biener & Abrams, 1991).
Self-efficacy for smoking reduction/cessation.
Along with stage of health behavior change, another outcome measure of this DNP
project is participant self-efficacy for smoking reduction and/or cessation. Self-efficacy is an
important outcome to measure because it reveals one’s beliefs in whether or not they have the
ability to partake in and/or complete certain behaviors and tasks (SAMHSA, 1999). Further,
self-efficacy is an important determinant of one’s position in the stages of change according to
the Transtheoretical Model (SAMHSA, 1999). Therefore, the Smoking Abstinence SelfEfficacy Questionnaire (SASEQ; see Appendix N) will be used to measure this outcome.
Developed by Spek et al. (2013), the SASEQ is a convenient, six-item scale used to measure
self-efficacy in regard to smoking cessation. The SASEQ has high internal consistency (α =
0.89), good discriminant validity, and good predictive validity (OR = 1.83; Spek et al., 2013).
Pharmacotherapy.
Another important measure of this project involves participant use of medication(s) to
assist them with smoking reduction and/or quitting. This is not to confuse the reader that
participants will be forced to utilize medication(s), as that is unethical. Rather, part of the
intervention involves educating and encouraging participants to utilize cessation medication(s) to
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help them combat the pharmacological aspect of nicotine addiction. Therefore, types of
cessation medication(s), and whether or not participants have received and are taking their
medication(s) will be recorded (see Appendix P).
Participant attendance.
Participant attendance is a key outcome measure, as it reflects interest in the program and
desire to be present. Attendance is also an important measure for program sustainability.
Therefore, participant attendance will be recorded at each group session.
Data collection procedures.
Upon defining the outcomes of interest for the DNP project, the next step is to identify
the data collection procedures. This step defines who, what, where, when, and how of the data
collection for this project. This next section lists the elements of the data collection process
according to the timeline in that it will be collected. A summary of this process may be found in
Appendix Q.
•

Enrollment Period (circa December 21st): The DNP student will collect all
baseline data on all group participants. This baseline data includes: the
enrollment form (Appendix K), the Contemplation Ladder (Appendix M), the
SASEQ (Appendix N), as well number of cigarettes smoked the day of enrollment
and exhaled CO levels (Appendix O). This data will be collected in the format of
paper surveys delivered face-to-face, and then will be de-identified upon
computer entry. Exhaled CO levels will be collected with the Covita™ piCO™ +
Smokerlyzer®. Data will be collected either at the CMHO or out in the
community at a safe and private location that is convenient for the participant. It
is important to note that some data on the enrollment form will not be used for
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data analysis. Rather, the DNP student will utilize this data to better-understand
the context of the participants’ addictions to tobacco. This information is
important for the development and delivery of CBT techniques that are relevant to
participants.
•

Group implementation (circa January 8th – February 25th): The DNP student will
collect all data on all group participants during the implementation period. This
data collection will take place once per week before each group session.
Collected data will include: participant attendance, the Contemplation Ladder
(Appendix M), the SASEQ (Appendix N), as well number of cigarettes smoked
that day and exhaled CO levels (Appendix O). This data will be collected in the
format of paper surveys delivered face-to-face.
o During this period, if participants are prescribed medication(s) to assist
with smoking reduction and/or quitting, the DNP student will manually
record what medication(s) each participant is prescribed and the DNP
student will verify by the next group session whether or not they received
and are taking their medication(s; Appendix P).

•

One month after implementation (circa March 25th): If any participants are able
to achieve smoking cessation during the program and maintain it until the end of
the program, the DNP student will contact these participants one month after
program end to inquire whether or not they have maintained abstinence. If so, an
attempt will be made to verify this self-report by obtaining exhaled CO levels
(Appendix O). This information will be manually recorded.
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Data management.
The DNP student is solely responsible for the management and storage of all collected
data for this DNP project. All data for this project will be collected through paper survey, and
will be organized according to data type and entered into a Microsoft® Excel spreadsheet. The
Excel spreadsheet will be kept on an encrypted flash drive that will be kept in a secure location at
the CMHO. It is important to understand that the enrollment form (Appendix K) does have
identifying data; however, participant enrollment forms will be kept at the CMHO in a secure
location, and they will not leave this location. After project completion, these forms will be
placed in the locked shred box within the CMHO. The enrollment form contains a line where
participants are assigned identification numbers. These identification numbers will be written in
place of identification data on paper surveys and Excel charting to ensure that data is collected in
an organized manner that de-identifies the participants.
Analysis.
The DNP student plans to meet with a Grand Valley State University statistician before
group implementation to ensure collected data will be entered electronically in a format that is
correct and most convenient for analysis. After this step is completed, the DNP student will then
electronically enter de-identified data as the DNP project progresses. Descriptive analysis will
be utilized to describe the sample of program participants. Items to be used for descriptive
analysis will include: age, psychiatric diagnoses, age of smoking initiation, amount of money
spent on cigarettes each day, and amount of previous quit attempts (if any). This data will likely
be displayed in table format.
Because the projected sample size (5-10 participants) for this DNP project is small,
descriptive statistics will be used to analyze collected data including: baseline and week 8
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average amount of cigarettes smoked per day, daily cigarette usage, exhaled CO levels, stage of
change, as well as self-efficacy. Because this data will be collected weekly for eight weeks, it is
likely that it will be displayed in line chart format to display trends over time. The collected data
will also be analyzed to determine if there are any statistical relationships between smoking
reduction/cessation behaviors with attendance, measured stage of change, as well as selfefficacy.
Resources & budget.
The development and implementation of a group smoking treatment program includes an
estimated budget (see Appendix R). The DNP student will donate to many of the costs of this
project. The DNP student will donate (3 hours) to development of staff survey on group
logistics. The DNP student will donate (1 hour) to meeting with the CMHO operations manager
to schedule the group room dates and times. The DNP student will donate (1 hour) to presenting
pre-enrollment and client education forms to the CMHO ACT teams during their morning
meetings. The DNP student will donate (5 hours) to the participant enrollment process. The
DNP student will donate (3 hours) to meeting with CMHO prescriber(s) and developing a plan
for smoking cessation pharmacotherapy for participants. Prior to group sessions, the DNP
student will donate (4 hours X 8 sessions) to planning topics and content for group sessions.
During group implementation, the DNP student will donate (1.5 hours X 8 sessions) to
conducting the group sessions. After each group session is completed, the DNP student will
donate (1 hour X 8 sessions) to data entry, and (1 hour X 8 sessions) to participant EHR charting.
Lastly, the DNP student will donate (30 minutes X 8 weeks) to rounding with the CMHO ACT
teams as well as provider(s). The DNP student is a staff nurse with an hourly wage of $29.04.
The total estimated donated cost for the DNP student is $2,336.08.
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It is also important to estimate the costs of utilizing CMHO staff time for project needs.
This time will be considered as donated to the DNP project as well. It is estimated one hour will
be spent with the operations manager ($17.90/hr; PayScale, 2018b). Five hours will be allotted
to ACT case workers ($20.32/hr; PayScale, 2018c) for filling-out pre-enrollment forms and
reviewing group education forms with interested clients. Lastly, seven hours will be allotted to
meeting with the NP ($48.25/hr; PayScale, 2018a) to devise a plan for pharmacotherapy as well
as time for the prescriber(s) to meet with clients and prescribe cessation medications. The total
estimated donated cost for the CMHO staff is $457.25.
In the state where the CMHO is located, it is estimated that tobacco smoking is
responsible for annual costs of $2.4 billion in lost productivity, $4.5 billion in premature death,
and $4 billion in direct medical expenditures (Rumberger, Hollenbeak, & Kline, 2010).
Reducing and/or quitting smoking results in decreased direct and indirect medical costs, and
increased work productivity (Rumberger et al., 2010). Further, it is estimated that $0.85-$2.44 is
saved for every dollar spent on smoking cessation programs (Rumberger et al., 2010). The
American Lung Association (2017) estimates that there is a return on investment (ROI) of $1.26
for every dollar spent on smoking cessation treatments. The DNP student discovered that the
reimbursement rate for group programs at the CMHO is $34.40 per participant, per session. It is
estimated that there will be at least five participants present per session. Therefore, it is
estimated that the CMHO will receive a total of $1,376 in reimbursement funds. Considering the
expenses, savings, and reimbursements associated with this project, the net operating plan is
estimated to be $5,016.25.
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Step 6: Integrate and maintain practice change.
Step 6 of the MEBPC involves “…sharing recommendations about the new practice with
stakeholders; incorporating the new evidence into the standards of care; monitoring the process
and outcome indicators; and celebrating and disseminating the results of the project” (Melnyk &
Fineout-Overholt, 2015). One aspect of Step 6 involves developing a plan for sustainability of a
project. The sustainability plan for this DNP project will be discussed in the next section.
Sustainability plan.
Sustainability of the group smoking treatment program is likely dependent upon the
success of the program. As described earlier, success will be determined by smoking reduction,
smoking cessation, sustained smoking cessation, forward movement in stages of change and selfefficacy for quitting, use of pharmacotherapy, and group session attendance. The plan is for the
DNP student to disseminate the results to CMHO stakeholders at the end of the program to
discuss results and sustainability. This discussion will be key to decide the feasibility of the
program, if any components should be altered or maintained, and future directions for the
program. This may include development of a program manual, grant requests for program
funding, as well as future DNP projects involving program analysis and quality improvement.
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Appendix A

Organizational Capacity

External Environment

• Administrative/Legal
• Political
• Social/Cultural
• Economic
• Stakeholder
• Technological
• Ecological

• Financial Management
• Program Management
• Process Management
• Inter-organizational Linkages
• Strategic Leadership
• Human Resources
• Infrastructure
• Structure

Or
Organizational
Performance
• Effectiveness
• Efficiency
• Relevance
• Financial Viability

Organizational
Motivation
•
•
•
•

History
Mission
Culture
Incentives/Rewards

Figure 1. IOA Model for organizational assessment. Adapted from Universalia.
http://www.universalia.com/en/services/institutional-and-organizational-performanceassessment
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Strengths
•
•
•
•
•

Mission supportive of evidence-based
practice
Program aligns with strategic map
Positive culture supporting client goals
and wellness
Staff and client buy-in
Physical space for group format

Weaknesses
•
•

Opportunities
•
•
•

Disparity in smoking rates among those
with and without SMI
Lack of structured smoking treatment
program within organization
Client interest in assistance with
smoking cessation

Reliance upon state for Medicaid
funding
Temporary changes in providers –
placing more pressure on sole provider
to meet client needs

Threats
•
•

Transportation to and from
organization
Sustainability of program likely
dependent upon success of program in
regard to smoking reduction or
cessation

Figure 2. SWOT Analysis of CMHO pertaining to a group smoking treatment program.
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Figure 3. Flow of article selection through literature review.
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Appendix D

Enter

Precontemplation

Maintenance

Action

Contemplation

Preparation

Exit and re-enter at any
stage

Figure 4. The Transtheoretical Model of Health Behavior Change. Adapted from Prochaska, J.
O., & Velicer, W. F. (1997). The transtheoretical model of health behavior change.
American Journal of Health Promotion, 12, 38-48.
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Performance
Accomplishments (ex:
past experience)

Vicarious Experience
(ex: modeling by
others)
Self-Efficacy
Judgments

Behavior/Performance

Social Persuasion (ex:
coaching and
evaluative feedback)

Physiological and
Emotional States

Figure 5. Model of Self-Efficacy. Adapted from Bandura, A. (1977). Self-efficacy: Toward a
unifying theory of behavioral change. Psychological Review, 84, 191-215.
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Model for Evidence-Based Practice Change

Step 1: Assess the need for change in
practice
• Include stakeholders
• Collect internal data about current
practice
• Compare external data with internal
data
• Identify problem
• Link problem, interventions, and
outcomes

Step 2: Locate the best evidence
• Identify types and sources of
evidence
• Review research concepts
• Plan the search
• Conduct the search

Step 6: Integrate and maintain change
in practice
• Communicate recommended change
to stakeholders
• Integrate into standards of practice
• Monitor processes and outcomes
periodically
• Celebrate and disseminate results of
project

Step 3: Critically analyze the evidence
• Critically appraise and weigh the
evidence
• Synthesize the best evidence
• Assess feasibility, benefits, and risks
of new practice

Step 5: Implement and evaluate
change in practice
• Implement pilot study
• Evaluate processes, outcomes, ad
costs
• Develop conclusions and
recommendations

Step 4: Design practice change
• Define proposed change
• Identify needed resources
• Design the evaluation of the pilot
• Design the implementation plan

Figure 6. The Model for Evidence-Based Practice Change. Adapted from Larrabee, J. H.
(2009). Nurse to nurse: Evidence-based practice. New York, NY: McGraw-Hill.
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Appendix H

11/27/18 – 11/30/18
Education of ACT teams
on dates/time of group.
Client pre-enrollment and
education forms distributed
to team members.

11/1/18
Survey emailed to
ACT
teams/management to
help inform group
logistics.

October

November

11/21/18
Meeting with
operations manager to
designate dates/times
for group, and
determine EHR input.

12/14/18
Meet with
CMHO
prescriber(s) to
develop plan for
prescribing
pharmacotherap
ies for
interested
participants.

1/8/19 – 2/25/19
Implementation of
group smoking
treatment program and
data collection.

12/21/18
Participant enrollment
and baseline
assessment completed.
ACT teams notified of
enrolled clients.

December

January

Week of 12/31/18
Participant reminder
calls placed.

12/7/18
Pre-enrollment
forms collected.

Figure 7. DNP project timeline.

Week of 4/15/19
Group smoking
treatment program
defense at Grand
Valley State
University.
Week of 3/11/19
Dissemination of
program results to
CMHO stakeholders.
Discussion on
sustainability.

February

March

April

3/8/19
Data analysis meeting
with statistician.
Week of 3/18/19
Development of
sustainability plan for
group smoking
treatment program.
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Appendix I

Are you interested in cutting back and/or becoming smoke
free from cigarettes?
Beginning Wednesday, January 9, XXXXXXXX will be hosting an 8week group smoking treatment program serving 10-15 XXXXXXXX
ACT team clients. A Grand Valley State University nurse practitioner
student will lead the group.
Group Location: XXXXXXXX group room.
Group Dates: Wednesdays for 8 weeks – January 9, January 16, January
23, January 30, February 6, February 13, February 20, and February 27.
Group Times: 1:30-2:30 pm.
Group Topics:
• How smoking affects you, your loved ones, and even your pets!
• Benefits of becoming smoke free.
• Boosting confidence and motivation to become smoke free.
• Medications to help you become smoke free, and how to
properly take them.
• Coping with the temporary side effects while your body
becomes less dependent on nicotine.
• How to prevent relapse to smoking.
• …and many more!
• You will also be given assistance with setting-up a meeting with
an XXXXXXXX prescriber if you desire to try medication
(such as nicotine replacement) to help you quit.

If you are interested in learning more about the group, please fill-out the
Pre-Enrollment form with your ACT team member. You will be
contacted soon after!
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Appendix J
Group Smoking Treatment Program Pre-Enrollment Form

Name: ________________________________

ACT Team: ____________________

Yes, I am interested in learning more about attending a group that teaches me how to become
smoke free from cigarettes.
I give permission to be contacted* at: _____________________________.

_________________________________________
Signature

___________________
Date

* If this client does not have an available phone number for contact, please notify Leah Magnuson of the best way to
reach them.

IMPROVING A MIDWESTERN COMMUNITY MENTAL HEALTH

56

Appendix K
Group Smoking Treatment Program Enrollment Form

Name: ____________________________________

Sex: _____

D.O.B.: _______________

Age: _______________

ACT Team: ____________________

Phone Number: ____________________________

Participant ID (for de-identification purposes): _______________
Psychiatric Diagnoses: ___________________________________________________________
Does this participant have any literacy issues? ________________________________________
How will this participant be transported to group?
______________________________________________________________________________

PATTERN AND CONTEXT OF CIGARETTE SMOKING
•

At what age did you start smoking? _______________

•

What prompted you to start smoking?

______________________________________________________________________________
______________________________________________________________________
•

How many cigarettes do you smoke per day? _______________
o How long have you been smoking at this level? _______________

•

How much money do you spend on cigarettes each day? _______________

•

What pack size do you buy? _______________

•

How soon after waking up do you smoke your first cigarette? _______________

IMPROVING A MIDWESTERN COMMUNITY MENTAL HEALTH
•

What was your longest time without a cigarette in the past week? _______________

•

Have you ever gone too long without a cigarette in that you began to notice withdrawal
symptoms? (i.e. irritability, difficulty concentrating, headaches, nausea, sweating, etc.)
Yes: ☐
No: ☐
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o If Yes, what were they, and how bad did they get?
______________________________________________________________________________
______________________________________________________________________
•

Have you ever tried to quit smoking in the past?
Yes: ☐
No: ☐
If Yes, how many times have you tried quitting? _______________
If Yes, when was your last quit attempt? _______________
If Yes, did you try using medication to help you quit?
Yes: ☐
No: ☐
If Yes, what medication (s) did you try?
________________________________________________________________
If Yes, for how long did you manage to stay smoke free after quitting in the past?
______________________________
What helped you stay smoke free during this time?
______________________________________________________
______________________________________________________

CONTEXT FOR SMOKING BEHAVIORS
•

Are there certain occasions where you feel it is particularly difficult to not to have a
cigarette?

______________________________________________________________________________
______________________________________________________________________________
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_____________________________________________________________________________
•

Are there certain occasions where you find it easier to abstain from smoking?

______________________________________________________________________________
______________________________________________________________________________
_____________________________________________________________________________
•

Are you currently living with anyone that smokes?
Yes: ☐
No: ☐

If Yes, what is their attitude towards smoking/quitting?
______________________________________________________________________________
______________________________________________________________________________
_____________________________________________________________________________
•

Are there people to support your decision to quit?
No: ☐
Yes: ☐

If Yes, who are they?
______________________________________________________________________________
______________________________________________________________________________
_____________________________________________________________________________

SMOKING-RELATED BACKGROUND INFORMATION
•

What are your interests and hobbies?

______________________________________________________________________________
______________________________________________________________________________
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___________________________________________________________________________
•

How are these associated with smoking? Can you do these activities without having a
cigarette?

______________________________________________________________________________
______________________________________________________________________________
_____________________________________________________________________________
•

Have you had any medical or health conditions related to your smoking?
Yes: ☐
No: ☐

______________________________________________________________________________
______________________________________________________________________________
_____________________________________________________________________________
•

Do you drink alcohol or use drugs that are not prescribed by a doctor?
No: ☐
Yes: ☐

______________________________________________________________________________
______________________________________________________________________________
_____________________________________________________________________________
•

What medications are you currently taking?

______________________________________________________________________________
______________________________________________________________________________
_____________________________________________________________________________
•

Are you currently experiencing any emotional difficulties or stressors?

______________________________________________________________________________
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Adapted from Stritzke, W., Chong, J., & Ferguson, D. (2009). Treatment manual for smoking
cessation groups: A guide for therapists. Cambridge, United Kingdom: Cambridge
University Press.
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Participant ID: _______________

Date: _______________
Week: _______________

10

9

8

Taking action to
quit (ex: cutting
down, enrolling in a
program)

Starting to think
about how to change
my smoking
patterns

7

6

5

Think I should quit
but not quite ready

4

3

2

Think I need to
consider quitting
someday

1
0

No thought of
quitting

Figure 7. Contemplation Ladder. Adapted from Biener, L., & Abrams, D. B. (1991). The
Contemplation Ladder: Validation of a measure of readiness to consider smoking
cessation. Health Psychology, 10, 360-365.
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The Smoking Abstinence Self-Efficacy Questionnaire

Participant ID: _______________

Date: _______________
Week: _______________

1. You feel agitated or tense. Are you confident that you will not smoke?
☐ Certainly

☐
☐
☐
☐

Probably
Neutral / Don’t know
Probably Not
Certainly Not

2. You are (very) angry. Are you confident that you will not smoke?
☐ Certainly

☐
☐
☐
☐

Probably
Neutral / Don’t know
Probably Not
Certainly Not

3. You are in a café, at a party, or paying a visit. Are you confident that you will not smoke?
☐ Certainly

☐
☐
☐
☐

Probably
Neutral / Don’t know
Probably Not
Certainly Not

4. You feel (very) sad. Are you confident that you will not smoke?
☐ Certainly

☐
☐
☐
☐

Probably
Neutral / Don’t know
Probably Not
Certainly Not
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5. Someone offers you a cigarette of your own brand. Are you confident that you will not
smoke?
☐ Certainly

☐
☐
☐
☐

Probably
Neutral / Don’t know
Probably Not
Certainly Not

6. You see someone enjoy smoking. Are you confident that you will not smoke?
☐ Certainly

☐
☐
☐
☐

Probably
Neutral / Don’t know
Probably Not
Certainly Not

The scores for the subsequent responses are the following:
Certainly = 4
Probably = 3
Neutral/Don’t know = 2
Probably Not = 1
Certainly Not = 0

Adapted from Spek, V., Lemmen, F., Chatrou, M., van Kempen, S., Pouwer, F., & Pop, V.
(2013). Development of a smoking abstinence self-efficacy questionnaire. International
Journal of Behavioral Medicine, 20, 444-449.
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Participant ID: _______________

Date: _______________
Week: _______________

Pre-Enrollment Cigarette Usage (for pre-enrollment and Week 8 only)
How many cigarettes does the participant smoke per day?

__________________

At Week 8, how many cigarettes does the participant smoke per day? __________________

Cigarette Usage
Have you smoked in the past week? (7 days)

☐ Yes

☐ No

Have you smoked today?

☐ Yes

☐ No

If yes, how many cigarettes have you smoked today? ______________

Carbon Monoxide Test

Time since last cigarette (minutes): _______________
CO (ppm) reading: _______________
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Pharmacotherapy for Smoking Reduction/Cessation

Participant ID: _______________

Date: _______________

Name of medication(s)/dosages for smoking treatment: _________________________

Has the participant received their medication(s)?
Yes: ☐
No: ☐

Is the participant taking their medication(s)?
Yes: ☐
No: ☐

Notes:

65

IMPROVING A MIDWESTERN COMMUNITY MENTAL HEALTH
Appendix Q

Outcome

How Measured

When Measured

Average number of
cigarettes smoked per day

Self-report (Appendix O)

Baseline (enrollment) and
Week 8 (conclusion) of
group program

Attendance

Recording of
presence/absence in a
Microsoft® Excel
spreadsheet

Weekly at the beginning of
group sessions

Has participant smoked in
the past week? Number of
cigarettes smoked before
group that day. Amount of
time since last cigarette.
Exhaled CO level(for
participant feedback, only).

Self-report and Covita™
piCO™ + Smokerlyzer®
(Appendix O)

Weekly at the beginning of
group sessions

Stage of health behavior
change related to smoking
cessation

Contemplation Ladder
(Appendix M)

Weekly at the beginning of
group sessions

Self-efficacy for smoking
reduction/cessation

Smoking Abstinence SelfEfficacy Questionnaire
(Appendix N)

Weekly at the beginning of
group sessions

Self-report

When prescribed and during
weekly follow-up with
participant

Prescription, receipt, and
use of smoking cessation
Pharmacotherapy
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Appendix R
Doctor of Nursing Practice Project Financial Operating Plan
Development and Integration of a Group Smoking Treatment Program into a
Midwestern CMHO
Revenue
DNP Student Time (in-kind donation)
CMHO Staff Time:
Nurse Practitioner
Case Workers
Operations Manager
Consultations
Statistician
Cost mitigation
Reimbursement for group participation
ROI: $1.26 saved for every $1.00 spent
TOTAL INCOME

2,236.08
337.75
101.60
17.90
100.00
1,376.00
4,096.63
8,265.96

Expenses
DNP Student Time (in-kind donation)
Team Member Time:
Nurse Practitioner
Case Workers
Operations Manager
Consultations
Statistician
Supplies
Treatment Manual for Smoking Cessation Groups: A Guide for Therapists
The SANE Smokefree Kit
Cognitive Behavioral Therapy for Smoking Cessation: A Practical Guidebook to the Most
Effective Treatments
Smokerlyzer®
20 ppm carbon monoxide calibration kit
D-pieces
Mouthpieces
Alcohol-free cleansing & antimicrobial wipes
Alcohol-free hand sanitizer
Copying/Printing
TOTAL EXPENSES
Net Operating Plan

2,236.08
337.75
101.60
17.90
100.00
20.00
40.00
6.81
75.00
195.00
48.50
37.50
15.00
8.57
10.00
3,249.71
5,016.25
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Structured Abstract
Background: Tobacco smoking is prevalent among those with serious mental illness. These
individuals consume half of the cigarettes sold in the United States, and account for nearly half of the
annual smoking-related deaths in the United States. Smoking plays a major role in the 25-year
decreased life expectancy individuals with serious mental illness have as compared to those in the
general population.
Objectives: To improve smoking rates, motivation for quitting, and self-efficacy for quitting by the
implementation of a group smoking treatment program within a community mental health
organization.
Methods: Evidence-based quality improvement methods were used to positively impact tobacco
smoking among clients served by a community mental health organization. This included
implementation of an 8-week group program, grounded in cognitive-behavioral therapy, along with a
process for prescribing smoking cessation medication for interested group participants.
Results: Seven men and three women participated in a total of seven group sessions. Mean decrease
in number of cigarettes smoked daily before group and mean increase in self-efficacy for smoking
reduction/cessation among participants. Impact on motivation for smoking cessation could not be
determined. Moderate negative correlation between number of cigarettes smoked and self-efficacy
for smoking reduction/cessation.
Conclusions: Group smoking treatment programs for those with serious mental illness positively
impact smoking rates and self-efficacy for smoking reduction/cessation.
Implications: Community mental health organizations are appropriate settings for evidence-based
smoking treatment for those with serious mental illness. Further study is needed on the design and
refinement of group smoking treatment programs for those with serious mental illness.
Keywords: Serious Mental Illness, Smoking Cessation, Group, Tobacco Treatment, Community
Mental Health
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Introduction
Tobacco smoking is an overwhelming habit among American adults with serious mental
illness (SMI), as it is estimated that nearly 67% of those with schizophrenia and 37% of those
with bipolar disorders smoke (Dickerson et al., 2018). Further, individuals with SMI smoke half
of the cigarettes sold in the United States (U.S.; Prochaska, Das, & Young-Wolff, 2017). Sadly,
individuals with SMI account for 200,000 of the 500,000 annual smoking-related deaths in the
U.S. (Colton & Manderschied, 2006). Individuals with SMI have a decreased life expectancy of
25 years compared to those without mental illness, with much of this disparity related to the
health effects of smoking (Colton & Manderschied, 2006).
Despite the staggering statistics on the prevalence of smoking in those with SMI, many of
these individuals desire to quit smoking and are able to do so if they are provided with
appropriate support (Prochaska et al., 2017). Evidence-based guidelines on smoking cessation
state that individuals with SMI require a combined approach of cognitive behavioral therapy
(CBT) and pharmacotherapy delivered in either an individual or group setting (Substance Abuse
and Mental Health Services Administration [SAMHSA], 2009). Although these guidelines exist,
many people with SMI experience barriers to assistance with smoking cessation. Some of these
barriers include health care provider beliefs, such as: people with SMI do not want to quit and
are not able to quit smoking; there are more important matters to discuss than smoking cessation;
and smoking cessation is dangerous for mental health (Prochaska et al., 2017).
This underlying knowledge provided an impetus for an organizational assessment (OA)
of a Midwestern community mental health organization (CMHO) in relation to its practices of
smoking treatment. The Institutional Organizational Assessment (IOA) Model was utilized as a
guide to assess three factors that influence organizational performance: 1) capacity, 2) external
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environment, and 3) motivation (Universalia, n.d.). Upon completion of the OA, a strengths,
weaknesses, opportunities, and threats (SWOT) analysis pertaining to the development and
implementation of an evidence-based group smoking treatment program within the CMHO was
completed.
A few key findings of the SWOT analysis influenced the progression of this Doctor of
Nursing Practice (DNP) project. First, there was immediate buy-in for a group smoking
treatment program from CMHO staff, administration, and clients. Staff and administration
understood the potential value of a group smoking treatment program, and clients were interested
in attending. Second, practices of treating nicotine addiction were limited. Clients were inquired
about their smoking habits upon intake during medication reviews, but were not asked if they
had thought about quitting. The CMHO prescribers were willing to prescribe medications,
however, it was up to clients to initiate conversation about quitting. Third, the CMHO was
familiar with running various groups and had a designated physical space for group activities;
therefore, the proposal of a new group was not a foreign concept to the organization.
A literature review was performed to inform this DNP project. The literature review
assisted the DNP student to further understand the clinical problem of tobacco smoking in those
with SMI as well as the safe and effective combined CBT and medication therapies for smoking
cessation treatment. The literature review reinforced combined CBT and pharmacotherapy as
safe and effective for smoking treatment in those with SMI (Bennett et al., 2015; Chengappa et
al., 2014; Garcia-Portilla et al., 2016). One study also concluded that individuals with SMI were
more likely to try smoking cessation medication when they received assistance with setting-up
meetings with prescribers and obtaining their prescriptions (Bennett et al., 2015). Last, nicotine
replacement therapy (NRT), bupropion, and varenicline, were all deemed as safe
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pharmacotherapies for smoking treatment in psychiatrically-stable individuals with SMI (Bennett
et al., 2015; Chengappa et al., 2014; Garcia-Portilla et al., 2016).
The results of the organizational assessment, SWOT analysis, and literature review, in
combination with the clinical practice problem of smoking in those with SMI, created the
impetus for this DNP project and led the DNP student to create the clinical practice question:
Does the design and implementation of an evidence-based group smoking treatment program
within the CMHO increase participant motivation and self-efficacy to quit smoking, as well as
decrease smoking rates? Therefore, the purpose of this DNP project was to design and
implement an evidence-based group smoking treatment program within a Midwestern CMHO to
foster participant motivation and self-efficacy for smoking cessation as well as to positively
impact smoking rates in a fashion sustainable to the CMHO. Specific objectives of this DNP
project included: 1) Group logistics (number of sessions, session length, session topics) were to
be mindfully structured according to The SANE Smokefree Kit (SANE Australia, 2009); 2) To
incorporate CBT techniques into group sessions to help foster self-confidence, motivation, and
skills to reduce and/or quit smoking; and 3) To develop a method in which group participants
interested in pharmacologic aids for smoking cessation could meet with CMHO prescriber(s) to
discuss options. The purpose of this manuscript is to discuss this DNP project in regard to its
implementation, results, and future implications.
Methods
Pre-Intervention Procedures
The Model for Evidence-Based Practice Change (MEBPC) guided the DNP student with
the steps and strategies for project implementation (see Figure 1). Strategies from the MEBPC
utilized for project design and implementation included:
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•

design of practice change (define proposed change, design implementation plan);

•

implementation and evaluation of change in practice (implement project, evaluate processes
and outcomes, develop conclusions and recommendations); and

•

integration and maintenance of change in practice (disseminate results project, communicate
recommended change to stakeholders; Larrabee, 2004).
Before explanation of the DNP project intervention, it is important to explain the

processes that preceded intervention implementation. Because this project included client
participation in a group, an enrollment process was developed. The consecutive steps for
participant enrollment included:
•

Raising awareness/distribution of education and pre-enrollment forms. The DNP
student presented to each of the CMHO’s Assertive Community Treatment (ACT)
teams and described the DNP project. During these meetings, the DNP student
distributed education forms as well as pre-enrollment forms. The DNP student
asked the ACT team case workers to present the group education forms to clients
interested in attending a smoking treatment group. If a client was interested in
learning more about the group, he or she would sign the pre-enrollment form and
record their phone number or the best means for contact. His or her ACT team
case worker then gave the pre-enrollment form back to the DNP student. The
DNP student allotted two weeks for case workers to return pre-enrollment forms.
It is recommended for groups with one facilitator to keep the group size between
5 – 10 participants (SANE Australia, 2009); however, the DNP student was given
permission by her DNP Project Advisory Team to enroll up to 15 participants, as
attrition was likely to occur.
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Enrollment. After the DNP student received a pre-enrollment form, she would call
the client and further disclose information about the group. If the client desired to
join the group, the DNP student would meet with the client either within the
CMHO or out in the community and complete the enrollment form as well as
collect baseline data (this data will be described later in the manuscript).

•

Notification of ACT teams. After a client officially enrolled into the group
smoking treatment program, his or her ACT team was notified via email.

Before project implementation, the DNP student worked with the CMHO operations
manager and support staff to designate a weekly date and time to reserve the group room for the
smoking treatment group. To promote attendance, the group would conclude a half an hour
before a different group commenced on addiction recovery. Therefore, participants were able to
attend both groups if they desired to do so. For charting and reimbursement purposes, support
staff created a template into the CMHO’s electronic charting system for the DNP student to
record attendance and interventions.
Intervention
SAMHSA guidelines (2009) encourage a combined approach of CBT and
pharmacotherapy for smoking cessation treatment in those with SMI. Therefore, the DNP
project intervention included the design and implementation of two aspects: an evidence-based
smoking treatment group, and a process for participants to receive smoking cessation medication.
Smoking treatment group.
The 8-week smoking treatment group, including session content and group length, was
designed according to the SANE Smokefree Kit (SANE Australia, 2009). The SANE Smokefree
Kit is an evidence-based manual used by healthcare professionals to assist with the development
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and implementation of smoking cessation groups for individuals with mental illness (SANE
Australia, 2009). The SANE Smokefree Kit (SANE Australia, 2009) offers eight weeks of group
session topics and activities, grounded in CBT, that target tobacco addiction in those with SMI.
The smoking treatment group’s weekly session aims and content, gleaned from the SANE
Smokefree Kit (SANE Australia, 2009), is available in Table 1. The DNP student also utilized
the Treatment Manual for Smoking Cessation Groups: A Guide for Therapists (Stritzke, Chong,
& Ferguson, 2009) and Cognitive-Behavioral Therapy for Smoking Cessation: A Practical
Guidebook to the Most Effective Treatments (Perkins, Conklin, & Levine, 2008) for
supplemental content and materials for the weekly sessions.
During the first group session, all participants were given a binder and a journal. When
participants came to group each week, they were given a packet of session content to place in
their binders. Each week, participants were given a homework assignment, of which they were
asked to complete in their journals. The DNP student also offered snacks and refreshments at
each group session.
Process for obtaining smoking cessation medication.
A binder of information on U.S. FDA-approved smoking cessation medications (NRT,
bupropion, varenicline; U.S. Food and Drug Administration, 2017) was created for the CMHO
prescriber. Information sheets on each drug included: mechanism of action, dosing, directions
for use, contraindications, side effects, and advantages/disadvantages for use. Patient education
sheets on directions for use were provided for each medication, and an information sheet on
electronic nicotine delivery systems was also included.
The DNP student met with the prescriber and reviewed the binder and prescribing
information on varenicline, bupropion, and NRT. Part of this meeting involved discussion on the
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safety and efficacy of varenicline in patients with SMI. The DNP student discussed the results of
the literature review, in that varenicline is safe in psychiatrically stable patients (Chengappa et
al., 2014; Garcia-Portilla et al., 2016). These results reflect that of a large, double-blind,
randomized, placebo-controlled trial testing the neuropsychiatric safety and efficacy of
varenicline in those with and without psychiatric disorders (Anthenelli et al., 2016). The authors
of this study concluded that there was no significant increase in moderate-to-severe SAEs
associated with varenicline in any participants, regardless of whether or not they had a
psychiatric disorder (Anthenelli et al., 2016). The results of this study led the FDA to remove
varenicline’s black box warning (Prochaska et al., 2017). Because group participants may not
have as stable of a psychiatric history, prescribing decisions would be based on the prescriber’s
clinical judgement regarding her knowledge and expertise of the participants’ mental well-being.
During this meeting, it was decided that group participants would be introduced to
setting-up meetings for pharmacotherapy during the second group session. Upon completion of
the second group session, emails were sent to the ACT teams and prescriber notifying them of
participants interested in smoking cessation medication. The ACT teams then collaborated with
the prescriber to help participants receive prescriptions. During each consecutive session after
the second session, the DNP student would ask participants if they had received a prescription,
whether or not they had received their medication, and if they were taking their medication. If
any previously-uninterested participants expressed interest in smoking cessation medication, the
DNP student would then send emails to ACT teams and the prescriber notifying them of the
participant’s interest. The next section of this manuscript will discuss the approach and
measures of the project intervention.
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Approach/Measures
The approach of this DNP project was that of a pre-post implementation comparison as
well as that of repeated measures over the series of eight group sessions. Table 2 provides a list
of the outcome measures for this project, including the tool used (if applicable), and when the
outcome was measured.
Attendance.
Participant attendance helps indicate whether or not an intervention is useful or
appropriate in a particular setting (McGuire, Bonfils, Kukla, Myers, & Salyers, 2013).
Therefore, attendance, or the presence or absence of participants at each group session, was
chosen as an outcome measure of this DNP project. It is an especially important outcome
measure considering that people with SMI may experience unique barriers to attending a group
(e.g., mental illness symptoms and transportation issues).
Stage of health behavior change.
Measuring change in smoking rate alone is inadequate when measuring the success of
smoking treatment (Rustin & Tate, 1993). Therefore, participant stage of health behavior change
was another outcome measure of this project. According to the Transtheoretical Model, health
behavior change occurs by the forward movement through six stages: precontemplation,
contemplation, preparation, action, and maintenance (Prochaska & Velicer, 1997). The
Contemplation Ladder was used to measure the participants’ stage of change in relation to
smoking cessation. The Contemplation Ladder has concurrent validity, as it is significantly
correlated with the likelihood of making a quit attempt within the next six months (p < .001;
Biener & Abrams, 1991).
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Self-efficacy for smoking reduction/cessation.
Another outcome measure of this DNP project was participant self-efficacy for smoking
reduction and/or cessation. Self-efficacy is described as one’s belief in whether or not they have
the ability to partake in and/or complete certain behaviors and tasks (SAMHSA, 1999). The
Smoking Abstinence Self-Efficacy Questionnaire (SASEQ) was used to measure self-efficacy
for smoking reduction and/or cessation. The SASEQ has high internal consistency (α = 0.89),
good discriminant validity, and good predictive validity (OR = 1.83; Spek et al., 2013).
Prescription, receipt, and use of smoking cessation pharmacotherapy.
SAMHSA (2009) guidelines state that individuals with SMI need CBT combined with
pharmacotherapy for smoking treatment. Therefore, an arm of this DNP project involved the
development of a process for participants to receive a prescription for FDA-approved smoking
cessation medication. Therefore, the prescription, receipt, and use of smoking cessation
medications by group participants were also considered outcome measures of the project.
During Week 2, the DNP student inquired with group participants on whether or not they were
interested in taking smoking cessation medication. The DNP student then sent an email to the
interested participants’ ACT teams and CMHO prescriber, notifying them of the participants’
desire. The DNP student then followed up with the participants during the weekly group
sessions on whether or not they had received and were taking their medication.
Smoking reduction.
Smoking reduction, or the self-reported decrease in the number of cigarettes smoked
daily, was the last outcome measure of this project. Upon pre-enrollment and at the conclusion
of the project (Week 8), participants were asked how many cigarettes they smoked on average
per day. To observe for small changes over the duration of the group, participants were also
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asked on a weekly basis: 1) whether or not they had smoked in the previous seven days; and (2
whether or not they had smoked that day; if so, how many cigarettes and how long since their
last cigarette (in minutes). Exhaled carbon monoxide (CO) levels were also obtained with the
Covita™ piCO™ + Smokerlyzer® to provide feedback and motivation to participants.
Participant feedback.
For project improvement and sustainability purposes, the DNP student created a survey
for group participants to complete during the last group session (Week 8). This 19-item, Likerttype survey is available in Appendix A. The survey asked participants to anonymously rate the
group program on several aspects: value, importance, learning, pharmacotherapy, and group
logistics.
Ethical Considerations
Consideration of ethics and protection for human subjects was required for this project.
The CMHO did not have an Institutional Review Board (IRB); therefore, the DNP student
utilized the Grand Valley State University Human Research Review Committee IRB for project
approval. This DNP project did not meet the qualifications of human research, and was
approved.
Analysis
The DNP student collected all data for this project. The data were then submitted to a
Grand Valley State University statistician to assist the DNP student with analysis and
interpretation of project results. Descriptive statistics and inferential statistics were utilized to
analyze project data. These results will be discussed next.
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Results
Participant Characteristics
In total, 11 participants, seven in whom were male and four in whom were female,
participated in the group smoking treatment program. One participant was a peer support worker
for the CMHO. To protect confidentiality and adhere to the project plan, baseline demographics
were not collected on this individual. Therefore, the use of the term participants refers to
participants enrolled in ACT services within the organization in this section, only.
Participants were between the ages of 30-68 years old. As shown in Figure 2, participant
primary psychiatric disorders consisted of schizophrenia, schizoaffective disorder, and bipolar
disorder. On average, participants began smoking at 16 years of age. At baseline (enrollment),
participants smoked on average about 19.88 cigarettes per day (note: an average pack size in the
U.S. is 20 cigarettes).
Attendance
According to the project plan, eight group sessions were planned. However, one group
session (Week 4) was cancelled due to inclement weather. Therefore, a total of seven group
sessions occurred. As shown in Table 3, 7 of 11 participants officially enrolled into the program.
Participants not considered officially enrolled were those who joined the group at a later time
than during the enrollment period. The average attendance per group session was around five
participants. On average, participants attended about 3 of 7 sessions (42.9%). Two participants
attended 100% of the sessions, and one participant did not attend any sessions.
Contemplation and Self-Efficacy for Smoking Reduction/Cessation
Table 4 and Figure 3 provide the participants’ Contemplation Ladder scores and group
mean over the duration of the 8-week program. There were mixed results. Six participants
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entered the program at a self-score of 10 (whether during enrollment or the week of first
attendance), indicating they were in the action stage of the Transtheoretical Model (Prochaska &
DiClemente, 1983; Biener & Abrams, 1991); two participants maintained this score throughout
their attendance to group sessions. Other participants experienced fluctuations in their
Contemplation Ladder scores during the program.
Table 5 and Figure 4 provide the participants’ SASEQ scores (i.e., one’s self-confidence
for smoking abstinence) and group mean over the duration of the 8-week program. There is
some variation in the participants’ personal scores week-by-week as well as variation in scores
amongst participants. However, all but one participant with two or more SASEQ measurements
experienced an increase in their last score when compared with their first score. Figure 4
supports this conclusion, as there was a slight increase in mean self-efficacy for smoking
cessation.
Smoking Reduction
Smoking reduction was measured in two ways: average number of cigarettes smoked preand post-implementation, and number of cigarettes smoked before group on group days. Data on
post-intervention rates of cigarettes smoked per day was limited, as only 3 of 7 participants who
provided pre-implementation smoking rates provided post-implementation rates. One
participant’s pre- and post-implementation rates remained the same at 20 cigarettes per day. The
second participant’s rate increased from 18 to 20 cigarettes per day. The third participant’s rate
decreased from 20 to 12 cigarettes per day. Unfortunately, no participants reported that they had
stopped smoking for a week, and there were only two occurrences during weeks 5 and 8 where a
participant reported that they had not smoked before group. Therefore, there is not enough
variance for comparison of these outcomes. Despite these conclusions, as shown in Figure 5,
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there was a slight decrease in the mean number of cigarettes smoked daily before group among
participants.
Table 6 provides the simple statistics and Pearson’s correlation coefficients summary
among the SASEQ scores, Contemplation Ladder scores, and number of cigarettes smoked daily
before group. There is a statistically significant correlation between participant SASEQ scores
and number of cigarettes smoked (p = 0.0064). As shown in Figure 5, there is a moderate,
negative association (r = -0.44579) between SASEQ scores and number of cigarettes smoked.
This indicates that lower SASEQ scores were associated with greater amounts of cigarettes
smoked that day. There was no statistically significant correlation between SASEQ scores and
Contemplation Ladder scores (p = 0.5999). There was also no statistically significant correlation
between Contemplation Ladder scores and number of cigarettes smoked (p = 0.3980).
Prescription, Receipt, and Use of Smoking Cessation Medication
During the second session of the group program, participants were asked whether or not
they were interested in receiving a prescription for smoking cessation medication. Emails were
sent to the ACT teams as well as prescriber for interested participants. During Week 2, one
participant was written a prescription for 14-mg, 24-hour nicotine patches and 2-mg nicotine
gum for breakthrough cravings. The participant received this medication, proceeded to take it
for one week, and then stopped for unknown reasons. Another participant was prescribed 14mg, 24-hour nicotine patches during Week 8. It is unknown whether or not the participant
received and used this medication, as the DNP student learned of the prescription after the
project concluded. Interestingly, a third participant was prescribed 14-mg, 24-hour nicotine
patches the week after the project concluded. It is unknown whether this participant received
and used the medication.
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Participant Feedback
Four participants completed the group smoking treatment program survey during the last
group session; their responses to survey questions are available in Figure 6. Overall, survey
results indicate that participants found value in the group and its session content, and believed
that the group helped them with smoking reduction behaviors (i.e., smoking reduction, increase
in length of time between cigarettes, more control over smoking). Interestingly, results were
varied for question 14: I think eight sessions was an appropriate amount for this group. During
discussion, a few participants mentioned that they wished for the smoking treatment group not to
end and that there were more sessions. This information is important to consider for
improvement and sustainability purposes.
Unintended Consequences/Missing Data
There were a few unintended consequences that led to missing data and data gaps. First,
one of the participants passed away from natural causes during the fourth week of the program.
Second, the fourth group session was canceled due to inclement weather. Third, four
participants joined the program after the enrollment period; therefore, no baseline data were
collected on these individuals. Fourth, many participants did not attend every group session.
Last, a couple of participants refused to partake in data collection during a few of the sessions.
Discussion
The results of this DNP project assist in answering the clinical question: Does the design
and implementation of an evidence-based group smoking treatment program within the CMHO
increase participant motivation and self-efficacy to quit smoking, as well as decrease smoking
rates? As explained earlier, six participants entered the program at the highest level of
motivation for change according to the Contemplation Ladder (Biener & Abrams, 1991). Some
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participants maintained high scores, while others fluctuated in their scores. Because many
participants entered the program at a high level of motivation, it cannot be determined if the
group smoking treatment program increased participant motivation to quit smoking. As the
Contemplation Ladder is not specific to those with SMI, it is possible there may have been
participant misperceptions and misunderstanding of what the Contemplation Ladder was
inquiring about. If a tool exists that measures level of motivation for health behavior change that
is specific to those with SMI, this would likely have been more appropriate for this project.
Perhaps then the results regarding motivation may have been different.
It is also interesting to note that there is variation in attendance upon comparison with
contemplation scores. One participant provided a self-score of 10 during enrollment, and did not
attend any group sessions. Another participant provided a self-score of 10 during enrollment and
attended every group session. The fluctuations in weekly scores along with the variance in
scores compared with attendance may indicate backward and forward movement through the
stages of change. Many individuals who attempt smoking cessation encounter this, as they
experience ambivalence and smoking lapses (Prochaska & DiClemente, 1983; Biener & Abrams,
1991).
Although there were fluctuations in participants’ SASEQ scores over the duration of the
group, it is encouraging that nearly all participants with two or more recorded SASEQ scores had
an increase in their last score as compared to their first score. Therefore, the group smoking
treatment program had a positive effect on self-efficacy. Interestingly, SASEQ scores were
significantly associated with the number of cigarettes smoked that day. Correlation does not
indicate causation; therefore, it cannot be deduced that higher self-efficacy scores caused lower
amounts of smoking. However, if a participant practiced cognitive and behavioral skills to
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reduce the amount he or she smoked before coming to group, it is plausible that he or she would
have felt empowered over his or her smoking, therefore rating self-efficacy higher than a
participant who had smoked a larger amount of cigarettes before coming to group.
Unfortunately, conclusions cannot be drawn on pre- and post-implementation averages of
cigarettes smoked per day due to lack of data. However, as evidenced by Figure 5, there was a
slight decrease in the mean number of self-reported cigarettes smoked by participants on group
days. Despite missing data, the outcomes of this DNP project answer the clinical question.
Although the program’s effects on participant motivation cannot be determined, the design and
implementation of an evidence-based group smoking treatment program within the CMHO did
increase participant motivation and self-efficacy to quit smoking, as well as decrease smoking
rates.
Another important discussion point concerns that of attendance. Two participants
attended every group session, while a third participant attended all but two sessions. By the end
of the program, these three participants experienced greater amounts of smoking reduction, as
well as celebrated more unmeasured, personal successes (i.e., increased length of time between
cigarettes, delay of smoking upon awakening in the morning) than their cohorts with less
attendance. These results indicate that attendance is likely important for reasons such as revisitation and reinforcement of weekly content and learned skills as well as continued peer and
facilitator support.
Although this DNP project answered the clinical question, there is room for
improvement. Many participants entered into the group highly motivated for smoking
reduction/cessation, but this does not indicate that these individuals had the knowledge or skills
to practice smoking reduction without assistance. These individuals would likely benefit from a
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personalized treatment plan in combination with group attendance. Personalized treatment may
include plans such as smoking cessation medication regimens and setting quit dates. Setting quit
dates would be beneficial for highly-motivated participants because it propels them into action
when they otherwise may remain in their smoking habits (Perkins et al., 2008).
An objective of this DNP project was to develop a process for interested participants to
obtain smoking cessation medication from the CMHO prescriber. Three participants received
prescriptions for NRT, but it is only known that one participant received this medication. Even
so, this participant took the medication for one week but then quit for unknown reasons. There is
a need for improvement in this process. Participants who receive cessation medication likely
need continued support with routine follow-up phone calls to ensure they understand the purpose
and need for the medication, as well as how to take it.
Results of the survey distributed during the Week 8 session reveal that participants were
overall very pleased with the group smoking treatment program. They believed the group to be
worthwhile and beneficial to smoking treatment. Participants also felt that the CMHO should
continue to offer the group, and that there were more than eight sessions.
Throughout the course of the group program, some participants also celebrated small
successes that were not captured with data collection. During one week, a participant reported
that he had been increasing the length of time between cigarettes to five hours. Another
participant celebrated her ability to wait two hours to smoke her first cigarette upon awakening
in the morning, after previously smoking within the first five minutes upon awakening. When
inquired about how she was able to accomplish this, the participant responded that she had been
delaying her smoking by practicing mindful breathing exercises she had learned in group. These
qualitative findings are also important to consider when gauging the success of this DNP project.
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Last, it is important to discuss the financial impact of this DNP project. For group
programs, the CMHO receives $34.40 per participant per session attended. Excluding the two
sessions attended by the peer support worker, there were a total of 35 attendance occurrences by
participants over the course of the 8-week program. Therefore, the CMHO received a total of
$1,204.00 in Medicaid reimbursement as a result of the group.
Limitations
A major limitation of this DNP project concerns that of missing data, and its effect on the
results. A few factors impacted data collection during this project: participants entering the
group past the enrollment period, participant attendance, refusal to complete data collection
forms, one week of missing data due to inclement weather, and the death of a participant. Also,
attendance and exhaled CO levels were the only objective measures of this project (exhaled CO
levels were not considered an outcome for this project, as they were used for motivation
purposes, only). All of the other measures were subjective (SASEQ, Contemplation Ladder,
number of cigarettes smoked, time since last cigarette); therefore, it is reasonable to question
their accuracy.
Although a group size of 5-10 participants was appropriate for this project (SANE
Australia, 2009), this is another limitation. Small sample sizes (e.g., number of participants) may
result in low statistical power, increased rates of false discovery, and decreased reproducibility
(Faber & Fonseca, 2014). Therefore, it is difficult to state with confidence that the results of this
project are translatable to similar practice settings. Because of a small sample size, this DNP
project may have been better analyzed with qualitative methods such as in-depth interviews,
focus groups, and content analysis.
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Another limitation to this DNP project is that during the time of implementation the
CMHO had only one prescriber (before project commencement, there had been three). At the
time, this prescriber was responsible for psychiatric evaluations, medication review
appointments, and psychiatric medication prescriptions for all of the clients serviced by the
CMHO. Therefore, this may have resulted in delays for smoking cessation medication
prescriptions. This limitation reveals that there is room for improvement in the process of
prescribing smoking cessation medication. Each ACT team has a designated registered nurse
who assists with medication distribution and provision. A future DNP project might focus on
streamlining prescription and receipt of cessation medication by utilizing the ACT team nurses.
Conclusion
In conclusion, the results of this DNP project reinforce that many people with SMI desire
to quit smoking (Prochaska et al., 2017). Although there is room for improvement, the group
smoking treatment program was successful because it positively impacted participant smoking
rates and self-efficacy for smoking reduction/cessation, and provided a small amount of revenue
to the CMHO. Participants and CMHO found value in the group program and there is a strong
desire from both parties for it to continue. There is a DNP student who plans on continuing this
project in the next year; however, CMHO staff and leadership want the group to continue before
next year. Therefore, the DNP student is planning to meet with CMHO leadership to discuss the
results of this project, as well as plan for sustainability. The DNP student plans on donating the
binder of weekly session content, the books and manuals used to create the binder, and the
Covita™ piCO™ + Smokerlyzer® and its supplies to the CMHO. If the group does continue,
this may provide beneficial quality improvement information to the incoming DNP student.
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Implications for Practice and Further Study
The smoking rate disparity between the general population (18%) and those with mental
illness (62% schizophrenia, 37% bipolar disorders) is alarming (Dickerson et al., 2018; Hall &
Doran, 2016). Cigarette smoking is the cause of many chronic illnesses and cancers, and the
main reason why people with SMI have a 25-year decreased life expectancy than those of the
general population (Colton & Manderschied, 2006). Also, the economic impact of tobacco
smoking is tremendous, as the U.S. loses more than $300 billion per year on smoking-related
illnesses (Xu, Bishop, Kennedy, Simpson, & Pechacek, 2015).
The disparity of smoking among those with SMI in combination with the devastating
health effects and economic impact of smoking provides the impetus for attention from the
healthcare arena. There needs to be a continued push to dispel myths and educate providers on
the facts of smoking and mental illness: many people with SMI want to quit smoking; many
people with SMI can quit smoking; and smoking cessation does not exacerbate mental illness
(Prochaska et al., 2017). Addressing the smoking habits in patients with SMI is a priority for
healthcare providers in every practice setting. The results of this DNP project indicate that
community mental health organizations are appropriate settings to implement evidence-based
smoking treatment for people with SMI. Future research is needed on the development and
refinement of group smoking treatment programs for those with SMI. Namely, programs that
offer combined pharmacotherapy and CBT group sessions that are specific to community mental
health settings.
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Tables
Table 1
Group Smoking Treatment Program Weekly Aims and Session Content
Week
1
•
•
•
•
2

•
•
•
•
•

3

•
•
•
•

4

•
•
•

Aims
Educate participants on group purpose, what to
expect, and session content.
Build cohesiveness among group members.
Increase knowledge on the composition of
cigarettes and the health effects of smoking and
secondhand smoke exposure.
Raise awareness on the reasons of smoking vs. the
reasons for becoming smoke free.
Review previous session, homework, and progress.
Build positive associations with becoming smoke
free.
Increase participants’ awareness of personal
strengths that may assist with becoming smoke
free.
Build participant confidence with becoming smoke
free.
Discuss plan for obtaining smoking cessation
medication for interested participants.

•
•
•
•
•
•
•
•
•
•

Review previous session, homework, and progress.
Build positive associations with becoming smoke
free.
Practice a method of how to deal with stress,
overcome a craving for a cigarette, as well as
manage nicotine withdrawal symptoms.
Develop a greater sense of the impact of smoking
on the body.

•
•

Review previous session, homework, and progress.
Raise awareness of personal triggers for smoking.
Increase knowledge of actions and behaviors one
may do to counter triggers for smoking and prepare
to become smoke free.

•
•

•
•
•

•
•
•

Content
Introductions
What’s in a cigarette/cigar?
Health effects of smoking &
secondhand smoke
“Why I Smoke” exercise
Homework – Reasons to
become smoke free
Session 1 recap
Homework discussion:
reasons to become smoke free
Strengths exercise & using
your strengths to help you
become smoke free
Setting-up meetings with
XXXXXXXXX for smoking
cessation medication
Homework – Activities not
related to smoking
Session 2 recap
Homework discussion:
activities not related to
smoking
The benefits of becoming
smoke free
Mindful breathing exercise
Homework – The impact of
smoking on my body &
mindful breathing practice
Session 3 recap
Homework discussion: impact
of smoking on my body &
mindful breathing practice
Triggers for smoking
Removing & avoiding triggers
for smoking
Homework – Behavioral
changes chart
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Table 1 (continued)
Week
5
•
•
•

Aims
Review previous session, homework, and progress.
Explore participants’ perceptions of stress and
promote healthy methods to cope with stress.
Identify negative thoughts and promote healthy
methods of managing negative thinking.

•
•
•
•
•
•

6

•
•

Review previous session, homework, and progress.
Encourage/educate/motivate participants with
healthy eating habits, exercise habits, and maintain
a healthy weight.

•
•
•
•
•

7

•
•
•
•
•
•

8

•
•
•
•

Review previous session, homework, and progress.
Identify high-risk situations to prevent relapse.
Review coping strategies for high-risk situations.
Discuss cravings and reinforce that they lead to a
choice for smoking.
Discuss the replacement of unhelpful thoughts
related to cravings with helpful thoughts to get
through cravings.
Normalize slip-ups (lapses), and explore coping
responses as a slip-up occurs.

•
•

Review previous session.
Celebrate the progress/achievements participants
have made individually and as a group.
Obtain participant feedback on the group through
survey and discussion.
Discuss the possible directions of the group
smoking treatment program.

•

•
•
•
•
•

•
•
•

Content
Session 4 recap
Homework discussion:
behavioral changes chart
Stress & smoking
Coping with stress
Identifying negative thoughts
& promoting positive thoughts
Homework – Positive
thoughts worksheet
Session 5 recap
Homework discussion:
positive thoughts worksheet
Healthy eating & maintaining
a healthy weight
Healthy living – Physical
activity
Homework – Setting goals
with healthy eating and
physical activity
Session 6 recap
Homework discussion: setting
goals with healthy eating and
physical activity
High-risk situations for
smoking & possible
management strategies
Things to do when you want
to smoke
Managing cravings
Dealing with slip-ups
The traffic light of lapses:
stop, think, do
Session 7 recap and group
journey
Future directions of group
Evaluation – Survey and
discussion
Lunch party!
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Table 2
Outcomes, Tool Used (if applicable), And When Outcome Was Measured

Outcome

How Measured

When Measured

Smoking reduction:
Decrease in number of
cigarettes smoked per day

Self-report

Baseline (enrollment) and
Week 8 (conclusion) of
group program

Attendance

Recording of
presence/absence in a
Microsoft® Excel
spreadsheet

Weekly at the beginning of
group sessions

Has participant smoked in
the past week? Number of
cigarettes smoked before
group that day. Amount of
time since last cigarette.
Exhaled CO level (for
participant feedback, only).

Self-report and Covita™
piCO™ + Smokerlyzer®

Weekly at the beginning of
group sessions

Stage of health behavior
change related to smoking
cessation

Contemplation Ladder

Weekly at the beginning of
group sessions

Self-efficacy for smoking
reduction/cessation

Prescription, receipt, and
use of smoking cessation
pharmacotherapy

Smoking Abstinence SelfEfficacy Questionnaire

Self-report

Weekly at the beginning of
group sessions
When prescribed
medication and during
weekly follow-up with
participant
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Table 3
Enrollment and Weekly Attendance of Group Participants
Participant
1

Official
Enrollment
O

2
3
4
5
6
7
8

Week 1 Week 2 Week 3
X
(New)
X
X

O
O
O
O
O
O

X
X
X

9

Week
4

Week
5
X

X
X

X

X
X
X
X
(New)

X
X
X

O - Officially Enrolled
X - Present
(New) - New This Week

6

Week
8

X
X

X
X

X
X
X

X

X

X

X

X

X

X
(New)

X
(New)

11
7

Week
7

X

10
Total
Participants

Week 6

7

5

4

4

X
X
X

2 (28.6%)
3 (42.9%)
2 (28.6%)
0
5 (71.4%)
7 (100%)
7 (100%)
5 (71.4%)
3 (42.9%)

X
5

Total Weeks
Attended
1 (14.3%)

2 (28.6%)
6
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Table 4
Participant Enrollment and Weekly Contemplation Ladder Scores
Participant Enrollment
Week 1
Week 2
Week 3
Week 4
Week 5
Week 6
Week 7
Week 8
1
10
10
2
8
3
5
8
10
2
4
10
8
10
5
10
6
8
8
10
10
10
7
7
7
8
8
8
10
10
8
8
10
10
10
10
10
10
10
10
10
9
10
10
10
9
3
10
11
10
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Table 5
Participant Enrollment and Weekly SASEQ Scores (Out of 24 Possible Points)
Participant Enrollment
Week 1
Week 2
Week 3
Week 4
1
8
2
5
3
7
14
15
19
4
3
4
7
5
6
6
6
16
6
7
7
4
6
17
8
10
11
9
9
9
24
10
11

Week 5
Week 6
14

6
10
9

14
8
16
17

Week 7

8
12
9
16

Week 8

8
10
12
6
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Table 6
Simple Statistics and Pearson’s Correlation Coefficients of Project Variables: SASEQ, Self-Reported Number of Cigarettes Smoked
and Level of Contemplation According to the Contemplation Ladder
Simple Statistics
Variable

N

Mean Std Dev

Sum Minimum Maximum Label

SASEQ

3 10.1315 4.8944 385.0000
8
8
0
0

3.00000

cig_today

3 4.57692 3.0273 178.5000
9
7
0

0

contemplation

3 8.81579 1.9431 335.0000
8
8
0

2.00000

24.00000 Sum of all self efficacy values (range 1-24)
12.00000 Number of cigarettes smoked today
10.00000 Self-reported level of contemplation from the
Contemplation Ladder

Pearson’s Correlation Coefficients
Prob > |r| under H0: Rho=0
Number of Observations
SASEQ cig_today contemplation
SASEQ

Sum of all self-efficacy values (range 1-24)
cig_today

Number of cigarettes smoked today

contemplation

Self-reported level of contemplation from the
Contemplation Ladder

1.00000 -0.44579
0.0064
38
36
0.44579
0.0064
36

1.00000
39

0.08787 -0.14525
0.5999
0.3980
38
36

0.08787
0.5999
38
-0.14525
0.3980
36
1.00000
38
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Figures

11/27/18 – 11/30/18
Education of ACT teams
on dates/time of group.
Client pre-enrollment
and education forms
distributed to team
members.
11/1/18
Survey emailed to
ACT
teams/management
to help inform group
logistics.

October

November

11/21/18
Meeting with
operations manager
to designate
dates/times for
group, and
determine EHR
input.

12/14/18
Meet with
CMHO
prescriber(s)
to develop
plan for
prescribing
pharmacother
apies for
interested
participants.

1/8/19 – 2/25/19
Implementation of
group smoking
treatment program
and data collection.

12/21/18
Participant
enrollment and
baseline assessment
completed. ACT
teams notified of
enrolled clients.

December

January

Week of 12/31/18
Participant reminder
calls placed.

12/7/18
Pre-enrollment
forms collected.

Week of 4/15/19
Group smoking
treatment program
defense at Grand
Valley State
University.
Week of 3/11/19
Dissemination of
program results to
CMHO
stakeholders.
Discussion on
sustainability.

February

March

April

3/8/19
Data analysis
meeting with
statistician.
Week of 3/18/19
Development of
sustainability plan
for group smoking
treatment program.

Figure 1. DNP project timeline as guided by The Model for Evidence-Based Practice Change.
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Bipolar
Disorder, 1

Schizophrenia ,
5
Schizoaffective
Disorder, 4

Figure 2. Number of group participants with schizophrenia, schizoaffective disorder, or bipolar
disorder as a primary psychiatric disorder.

IMPROVING A MIDWESTERN COMMUNITY MENTAL HEALTH

103

Self-reported level of contemplation from the
Contemplation Ladder

10

8

6

4

2
0

2

4

6

8

Week of the program. Week 0 = baseline (before group initiation)
Participants identification number
1
7

2
8

3
9

4
10

5
11

6
Mean

Figure 3. Participant self-reported level of contemplation from the Contemplation Ladder, measured over the course of the 8-week
group smoking treatment program.
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Sum of all self efficacy values (range 1-24)

25

20

15

10

5

0

2

4

6

8

Week of the program. Week 0 = baseline (before group initiation)
Participants identification number
1
7

2
8

3
9

4
10

5
11

6
Mean

Figure 4. Participant self-reported self-efficacy scores for smoking reduction/cessation from the SASEQ, measured over the course of
the 8-week group smoking treatment program.
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Number of cigarettes smoked today

12.5

10.0

7.5

5.0

2.5

0.0
0

2

4

6

8

Week of the program. Week 0 = baseline (before group initiation)
Participants identification number
1
7

2
8

3
9

4
10

5
11

6
Mean

Figure 5. Participant self-reported number of cigarettes smoked on group days, measured over the course of the 8-week group
smoking treatment program.
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Sum of all self efficacy values (range 1-24)

25

20

15

10

5

0.0

2.5

5.0

7.5

10.0

12.5

Number of cigarettes smoked today
Figure 5. Scatterplot revealing moderate negative association between SASEQ scores and amount of cigarettes smoked that day.
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Number of Responses

4

3
Strongly Agree
Agree

2

Neutral

Disagree

Strongly Disagree

1

0

1

2

3

4

5

6

7

8

9
10
11
12
Question Number

Figure 6. Participant responses to survey questions.
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Appendices
Appendix A

Group Smoking Treatment Program Survey

Please fill-in the bubble that most closely reflects how you feel.
1) To me, it is important to learn about things I can do (behaviors) and ways in
which I can think (cognition) to help me with smoking cessation.

2) I need smoking cessation medication to help me quit smoking.

3) This group was worthwhile to me.

4) This group taught me things I can do (behaviors) to help me quit smoking.
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5) This group taught me ways in which I can think (cognition) to help me quit
smoking.

6) This group helped me reduce the amount I smoke.

7) This group helped me increase the length of time I can go between having
cigarettes.

8) I have more control over my smoking now than when I did before the group
started.

9) I believe that I am more able to quit smoking now than I was before the group
started.
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10) I enjoyed receiving a binder with information given to me weekly.

11) It was valuable to see what my exhaled carbon monoxide levels were each
week.

12) Seeing my exhaled carbon monoxide levels motivated me to reduce the amount
that I smoke.

13) Seeing my exhaled carbon monoxide levels helped me realize that smoking is
indeed bad for my health.

14) I think that eight sessions was an appropriate amount for this group.
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15) I think that an hour a week was enough time for the group.

16) XXXXXXXX should continue to offer a group smoking treatment program.

17) This group properly assisted me with obtaining smoking cessation mediation if
I asked for it.

18) The weekly topics were relevant to my smoking.

19) I would continue to attend this group if more sessions were available.

